ID;Study ID;Reference;Grouping;Victim;Perpetrator;Route Victim;Route Perpetrator;Mechanism;Compartment;AUCR Avg;AUCR AvgType;AUCR Var;AUCR VarType;CmaxR Avg;CmaxR AvgType;CmaxR Var;CmaxR VarType;t_placebo_0;t_placebo_end;t_treatment_0;t_treatment_end;t Unit;R Dose correction factor;Comment;Dose;Dose free API;Dose Unit;Route;Times of Administration;Times Unit;Description;Comment Regimen;Administered form;Formulation type;Infusion duration [min];Water volume ingested for drug intake [mL];Comment on administration/formulation;Fasted/Fed state;Duration of fasting before drug administration [h];Duration of fasting after drug administration [h];Comment on food intake
50;Ahonen 1995;http://www,ncbi,nlm,nih,gov/pubmed/8527290;with Perpetrator (Itraconazole);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;5,745098039;Approx, Avg;;;2,558823529;Approx, Avg;;;0;inf;74;inf;h;;;100;;mg;PO;(S-0,T-24,R-4);h;MD OD (4 days);OD;;Sporanox;;;Sporanox Janssen;;;;
54;Backman 1996;https://www,ncbi,nlm,nih,gov/pubmed/8549036;with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;41;Arith,mean;;;0,061818182;Approx, CmaxR;;;0;inf;113;inf;h;1;;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);;;300 mg capsules, Rimapen Orion;;;;;;;
56;Backman 1998;https://www,ncbi,nlm,nih,gov/pubmed/9591931;Phase IV (during Perpetrator (Rifampicin));Midazolam;Rifampicin;PO;PO;Induction;Plasma;23;arith, mean;6;Arith, SEM;54;Arith, Mean;12;Arith, SEM;0;inf;113;185;h;1;;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);;;300 mg capsules, Rimapen Orion;;;;Fasted;;;
57;Backman 1998;https://www,ncbi,nlm,nih,gov/pubmed/9591931;Phase V (4 days after Perpetrator (Rifampicin));Midazolam;Rifampicin;PO;PO;Induction;Plasma;132;arith, mean;28;Arith, SEM;202;Arith, Mean;42;Arith, SEM;0;inf;185;inf;h;1;;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);;;300 mg capsules, Rimapen Orion;;;;Fasted;;;
58;Backman 1998;https://www,ncbi,nlm,nih,gov/pubmed/9591931;Phase II (during Perpetrator (Itraconazole));Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;7,97;arith, mean;1,14;Arith, SEM;3,12;Arith, Mean;0,37;Arith, SEM;0;inf;74;170;h;1;Cave! Different dose treatment vs control, Ratios are dose-corrected,;200;;mg;PO;0-24-48-72;h;MD OD (4 days);;;Sporanox 100-mg capsule;;;;Fasted;;;
59;Backman 1998;https://www,ncbi,nlm,nih,gov/pubmed/9591931;Phase III (4 days after Perpetrator (Itraconazole));Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;2,63;arith, mean;0,4;Arith, SEM;1,92;Arith, Mean;0,31;Arith, SEM;0;inf;170;inf;h;1;Cave! Different dose treatment vs control, Ratios are dose-corrected,;200;;mg;PO;0-24-48-72;h;MD OD (4 days);;;Sporanox 100-mg capsule;;;;Fasted;;;
113;Chung 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580903;with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,124489796;Approx, Avg;;;0,169565217;Approx, CmaxR;;;0;inf;166;inf;h;1;;600;;mg;PO;S0-T24-R9;h;MD OD (9 days);;300-mg capsules (UDL);;;;2x 300 mg capsules;;;;
114;Chung 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580903;with Perpetrator (Ketoconazole);Midazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;9,510204082;Approx, Avg;;;2,391304348;Approx, CmaxR;;;0;inf;118;inf;h;;;400;;mg;PO;(S-0,T-24,R-10);h;MD OD (10 days);;200-mg tablets (Taro);;;;2x 200 mg tablets;;;;
116;Chung 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580903;with Perpetrator (Rifampicin);Simvastatin;Rifampicin;PO;PO;Induction;Plasma;0,089655172;Approx, Avg;;;0,148648649;Approx, CmaxR;;;0;inf;190;inf;h;1;;600;;mg;PO;S0-T24-R9;h;MD OD (9 days);;300-mg capsules (UDL);;;;2x 300 mg capsules;;;;
117;Chung 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580903;with Perpetrator (Ketoconazole);Simvastatin;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;12,55172414;Approx, Avg;;;7,432432432;Approx, CmaxR;;;0;inf;190;inf;h;;;400;;mg;PO;(S-0,T-24,R-10);h;MD OD (10 days);;200-mg tablets (Taro);;;;2x 200 mg tablets;;;;
129;Eap 2004;https://www,ncbi,nlm,nih,gov/pubmed/15114429;0,075 mg with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,441176471;Approx, Avg;;;0,225806452;Approx, Avg;;;0;inf;90;114;h;1;;450;;mg;PO;S0-T24-R5;h;MD OD (5 days);QD;;;;;;;;;
130;Eap 2004;https://www,ncbi,nlm,nih,gov/pubmed/15114429;0,075 mg with Perpetrator (Ketoconazole);Midazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;6,470588235;Approx, Avg;;;3,741935484;Approx, Avg;;;0;inf;48;inf;h;;;200;;mg;PO;0-12-24-36;h;MD BID (2 days);BID;;;;;;;;;
132;Eap 2004;https://www,ncbi,nlm,nih,gov/pubmed/15114429;7,5 mg with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,052238806;Approx, Avg;;;0,111538462;Approx, Avg;;;0;inf;114;inf;h;1;;450;;mg;PO;S0-T24-R5;h;MD OD (5 days);QD;;;;;;;;;
173;Gorski 1998;https://www,ncbi,nlm,nih,gov/pubmed/9728893;po with Perpetrator (Clarithromycin);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Whole Blood;7,142857143;Approx, Avg;;;;;;;0;inf;146;inf;h;;from CL (L/hr/kg);500;;mg;PO;0-(S12-T12-R13);h;MD BID (7 days);MD;;pill;;;;;;;
175;Gorski 1998;https://www,ncbi,nlm,nih,gov/pubmed/9728893;iv with Perpetrator (Clarithromycin);Midazolam;Clarithromycin;IV;PO;Mechanism_based_Inactivation;Whole Blood;2,666666667;Approx, Avg;;;;;;;0;inf;146;inf;h;;from CL (L/hr/kg);500;;mg;PO;0-(S12-T12-R13);h;MD BID (7 days);MD;;pill;;;;;;;
177;Gorski 2003;https://www,ncbi,nlm,nih,gov/pubmed/12966371;po with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Whole Blood;0,103351955;Approx, Avg;;;0,100558659;arith, Mean;;;0;inf;132;inf;h;1,5;Cave! Different dose treatment vs control,;600;;mg;PO;S0-T24-R7;h;MD OD (7 days);MD;;pill, INN, rifampicin;;;;;;;
179;Gorski 2003;https://www,ncbi,nlm,nih,gov/pubmed/12966371;iv with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Whole Blood;0,448979592;Approx, Avg;;;;;;;0;inf;132;inf;h;1;;600;;mg;PO;S0-T24-R7;h;MD OD (7 days);MD;;pill, INN, rifampicin;;;;;;;
191;Greiner 1999;https://www,ncbi,nlm,nih,gov/pubmed/10411543;po with Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Plasma;0,697080292;Approx, Avg;;;0,481481481;Approx, Avg;;;0;inf;240;inf;h;1;;600;;mg;PO;S0-T24-R16;h;MD OD (16 days);MD;rifampin;RIFA Gr�nenthal GmbH;;;;;;;
193;Greiner 1999;https://www,ncbi,nlm,nih,gov/pubmed/10411543;iv with Perpetrator (Rifampicin);Digoxin;Rifampicin;IV;PO;Induction;Plasma;0,853379152;Approx, Avg;;;0,834008097;Approx, Avg;;;0;inf;240;inf;h;1;;600;;mg;PO;S0-T24-R16;h;MD OD (16 days);MD;rifampin;RIFA Gr�nenthal GmbH;;;;;;;
215;Gurley 2006;https://www,ncbi,nlm,nih,gov/pubmed/16432272;with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,057160804;Approx, Avg;;;0,120915033;arith, Mean;;;0;inf;146;inf;h;1;;300;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD;Rifampin;300mg, Rifadinﾮ, Aventis Pharmaceuticals;;;twice daily;;;;
217;Gurley 2006;https://www,ncbi,nlm,nih,gov/pubmed/16432272;with Perpetrator (Clarithomycin);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;8,39285714;Approx, Avg;;;3,795597484;arith, Mean;;;0;inf;146;inf;h;;;500;;mg;PO;(S-0,T-12,R-14);h;MD BID (7 days);MD;clarithromycin;500 mg, Biaxinﾮ, Abbott Laboratories;;;twice daily;;;;
221;Gurley 2008a;https://www,ncbi,nlm,nih,gov/pubmed/17495878;with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,06031746;Approx, Avg;;;0,107623318;arith, Mean;;;0;inf;146;inf;h;1;;300;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD;Rifampin;300mg, Rifadinﾮ, Aventis Pharmaceuticals;;;twice daily;;;;
223;Gurley 2008a;https://www,ncbi,nlm,nih,gov/pubmed/17495878;with Perpetrator (Clarithomycin);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;5,4833984;Approx, Avg;;;2,174329502;arith, Mean;;;0;inf;146;inf;h;;;500;;mg;PO;(S-0,T-12,R-14);h;MD BID (7 days);MD;clarithromycin;500 mg, Biaxinﾮ, Abbott Laboratories;;;twice daily;;;;
227;Gurley 2008b;https://www,ncbi,nlm,nih,gov/pubmed/18214850;with Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Serum;0,69565217;Approx, Avg;;;0,615384615;arith, Mean;;;0;inf;146;inf;h;1;;300;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD;Rifampin;Rifadinﾮ, Aventis Pharmaceuticals;;;twice daily;;;;
229;Gurley 2008b;https://www,ncbi,nlm,nih,gov/pubmed/18214850;with Perpetrator (Clarithomycin);Digoxin;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Serum;1,46575342;Approx, Avg;;;1,75;arith, Mean;;;0;inf;144;inf;h;;;500;;mg;PO;(S-0,T-12,R-14);h;MD BID (7 days);MD;clarithromycin;Biaxinﾮ, Abbott Laboratories;;;twice daily;;;;
271;Jalava 1997;https://www,ncbi,nlm,nih,gov/pubmed/9421099;po with Perpetrator (Itraconazole);Digoxin;Itraconazole;PO;PO;Reversible_Inhibition;Serum;168;arith, Mean;;;134;arith, Mean;;;0;inf;49;inf;h;;;200;;mg;;0-24-48-72-96;;MD OD (5 days);;;Sporanox 100-mg caps, Janssen Pharmaceuticals, Beerse, Belgium;;120;;;;;
276;Kharasch 1997;https://www,ncbi,nlm,nih,gov/pubmed/9232132;with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,379310345;Approx, Avg;;;;;;;0;inf;120;inf;h;1;AUCR estimated from CL ratio;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);MD;;;;;;;;;
278;Kharasch 1997;https://www,ncbi,nlm,nih,gov/pubmed/9232132;with Perpetrator (Rifampicin);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,363013699;Approx, Avg;;;;;;;0;inf;120,5;inf;h;1;AUCR estimated from CL ratio;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);MD;;;;;;;;;
280;Kharasch 2004;https://www,ncbi,nlm,nih,gov/pubmed/15536460;iv with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,521126761;Approx, Avg;;;1,009960159;Approx, CmaxR;;;0;inf;104;128;h;1;;600;;mg;PO;S0-T24-R6;h;MD OD (6 days);MD OD;;;;;;;;;
283;Kharasch 2004;https://www,ncbi,nlm,nih,gov/pubmed/15536460;iv with Perpetrator (Rifampicin);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;375;Approx, Avg;;;1,003325942;Approx, CmaxR;;;0;inf;105;129;h;1;;600;;mg;PO;S0-T24-R6;h;MD OD (6 days);MD OD;;;;;;;;;
286;Kharasch 2004;https://www,ncbi,nlm,nih,gov/pubmed/15536460;po #1 with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,052631579;Approx, Avg;;;0,10989011;Approx, CmaxR;;;0;inf;128;inf;h;1;;600;;mg;PO;S0-T24-R6;h;MD OD (6 days);MD OD;;;;;;;;;
288;Kharasch 2004;https://www,ncbi,nlm,nih,gov/pubmed/15536460;po #1 (60 ﾵg/kg) with Perpetrator (Rifampicin);Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,045631068;Approx, Avg;;;0,111111111;Approx, CmaxR;;;0;inf;129;inf;h;1;;600;;mg;PO;S0-T24-R6;h;MD OD (6 days);MD OD;;;;;;;;;
294;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 5 mg);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,84;geo, Mean;0,13;+/- 90%CI;1,03225806;arith, Mean;;;0;inf;108;132;h;1;;5;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
295;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 10 mg);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,77;geo, Mean;0,12;+/- 90%CI;1,064516129;arith, Mean;;;0;inf;108;132;h;1;;10;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
296;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 25 mg);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,63;geo, Mean;0,11;+/- 90%CI;0,838709677;arith, Mean;;;0;inf;108;132;h;1;;25;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
297;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 75 mg);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,6;geo, Mean;0,12;+/- 90%CI;1,322580645;arith, Mean;;;0;inf;108;132;h;1;;75;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
299;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 5 mg);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,83;geo, Mean;0,16;+/- 90%CI;1,039215686;arith, Mean;;;0;inf;109;133;h;1;;5;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
300;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 10 mg);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,75;geo, Mean;0,15;+/- 90%CI;1,049019608;arith, Mean;;;0;inf;109;133;h;1;;10;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
301;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 25 mg);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,59;geo, Mean;0,12;+/- 90%CI;1;arith, Mean;;;0;inf;109;133;h;1;;25;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
302;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;iv with Perpetrator (Rifampicin @ 75 mg);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,51;geo, Mean;0,12;+/- 90%CI;1,029411765;arith, Mean;;;0;inf;109;133;h;1;;75;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
304;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 5 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,8;geo, Mean;0,19;+/- 90%CI;0,8;arith, Mean;;;0;inf;132;inf;h;1;;5;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
305;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 10 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,68;geo, Mean;0,17;+/- 90%CI;0,93333333;arith, Mean;;;0;inf;132;inf;h;1;;10;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
306;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 25 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,4;geo, Mean;0,1;+/- 90%CI;0,506666667;arith, Mean;;;0;inf;132;inf;h;1;;25;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
307;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 75 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,25;geo, Mean;0,09;+/- 90%CI;0,34;arith, Mean;;;0;inf;132;inf;h;1;;75;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
309;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 5 mg);Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,74;geo, Mean;0,16;+/- 90%CI;0,862745098;arith, Mean;;;0;inf;133;inf;h;1;;5;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
310;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 10 mg);Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,61;geo, Mean;0,23;+/- 90%CI;0,862745098;arith, Mean;;;0;inf;133;inf;h;1;;10;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
311;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 25 mg);Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,3;geo, Mean;0,1;+/- 90%CI;0,490196078;arith, Mean;;;0;inf;133;inf;h;1;;25;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
312;Kharasch 2011;https://www,ncbi,nlm,nih,gov/pubmed/21562488;po with Perpetrator (Rifampicin @ 75 mg);Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,13;geo, Mean;0,06;+/- 90%CI;0,254901961;arith, Mean;;;0;inf;133;inf;h;1;;75;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampin;capsules;;;at bedtime;;;;
314;Kirby 2012;https://www,ncbi,nlm,nih,gov/pubmed/22190694;Study 1 - Staggered Administration with RIF;Digoxin;Rifampicin;PO;PO;Induction;Plasma;0,81;geo, Mean;;;0,78;geo, Mean;;;0;inf;324;inf;h;1;;600;;mg;PO;S0-T24-R14;h;MD OD (14 days);QD;rifampin;300-mg capsules Novartis;;;;;;;
316;Kirby 2012;https://www,ncbi,nlm,nih,gov/pubmed/22190694;Study 2 - Simultaneous Administration with RIF;Digoxin;Rifampicin;PO;PO;Induction;Plasma;1,25;geo, Mean;;;1,55;geo, Mean;;;0;inf;360;inf;h;1;;600;;mg;PO;S0-T24-R14;h;MD OD (14 days);QD;rifampin;300-mg capsules Novartis;;;;;;;
318;Kivist� 1997;https://www,ncbi,nlm,nih,gov/pubmed/9333111;with Perpetrator (Erythromycin);Buspirone;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;5,9;;;;5;;;;0;inf;79;inf;h;;;500;;mg;PO;0-6-14-24-30-38-48-54-62-72-78;h;MD TID (3 days);MD;erythromycin base;Ery-Max 250 mg enterocapsule;;150;;Fasted;2;3;wrt, administration of buspirone
320;Kivist� 1997;https://www,ncbi,nlm,nih,gov/pubmed/9333111;with Perpetrator (Itraconazole);Buspirone;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;19,2;;;;13,4;;;;0;inf;79;inf;h;;;100;;mg;PO;0-6-24-30-48-54-72-78;h;MD BID (3 days);MD;;Sporanox;;150;;Fasted;2;3;wrt, administration of buspirone
327;Lamberg 1998a;https://www,ncbi,nlm,nih,gov/pubmed/9923581;with Perpetrator (Fluvoxamine);Buspirone;Fluvoxamine;PO;PO;Reversible_Inhibition;Plasma;2,35;;0,75-4,69;Range;2,01;;0,69-3,96;Range;0;inf;114;inf;h;;;100;;mg;PO;0-24-48-72-96;h;MD OD (5 days);SD;;Fevarin;;150;;Fasted;2;3;wrt, administration of buspirone
329;Lamberg 1998b;https://www,ncbi,nlm,nih,gov/pubmed/9578186;with Perpetrator (Rifampicin);Buspirone;Rifampicin;PO;PO;Induction;Plasma;104;;0,063-0,145;95% CI;163;;0,101-0,226;95% CI;0;inf;113;inf;h;1;;30;;mg;PO;0-24-48-72-96;h;MD OD (5 days);SD;;Rimapen Orion;;150;;Fasted;2;3;wrt, administration of buspirone
331;Lamberg 1998c;https://www,ncbi,nlm,nih,gov/pubmed/9663178;with Perpetrator (Verapamil);Buspirone;Verapamil;PO;PO;Mechanism_based_Inactivation;Plasma;3,4;;;;3,4;;;;0;inf;30;inf;h;;;80;;mg;PO;0-5-12-24-29;h;;SD;;Verapamil tablet Orion;;150;;Fasted;2;3;wrt, administration of buspirone
333;Lamberg 1998c;https://www,ncbi,nlm,nih,gov/pubmed/9663178;with Perpetrator (Diltiazem);Buspirone;Diltiazem;PO;PO;Mechanism_based_Inactivation;Plasma;5,5;;;;4,1;;;;0;inf;30;inf;h;;;60;;mg;PO;0-5-12-24-29;h;;SD;;Diltiazem tablet Orion;;150;;Fasted;2;3;wrt, administration of buspirone
337;Larsen 2007;https://www,ncbi,nlm,nih,gov/pubmed/17365992;with Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Serum;0,817346939;Approx, Avg;;;;;;;0;inf;144;inf;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;;;;;;;;;
338;Larsen 2007;https://www,ncbi,nlm,nih,gov/pubmed/17365992;with Perpetrator (Ketoconazole);Digoxin;Ketoconazole;PO;PO;Reversible_Inhibition;Serum;1,091836735;Approx, Avg;;;;;;;0;inf;96;inf;h;;;200;;mg;PO;0-24-48-72;h;MD OD (5 days);MD;;;;;;;;;
2036;Kim 2018;https://www,ncbi,nlm,nih,gov/pubmed/28877336;Midazolam + Rifampicin Male;Midazolam;Rifampicin;IV;PO;Induction;Plasma;1,15;geom, Mean (GMR);1,025 - 1,275;90% CI;;;;;0;inf;216;inf;h;2,5;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control),;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;rifampicin;oral formulation;;;;;;;
2039;Kim 2018;https://www,ncbi,nlm,nih,gov/pubmed/28877336;Midazolam + Rifampicin Female;Midazolam;Rifampicin;IV;PO;Induction;Plasma;1225;geom, Mean (GMR);1,15 - 1,325;90% CI;;;;;0;inf;216;inf;h;2,5;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control),;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;rifampicin;oral formulation;;;;;;;
354;Markert 2013;https://www,ncbi,nlm,nih,gov/pubmed/23748747;with Perpetrator (Clarithromycin);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;5,555555556;geo, Mean?;4,76190476190476-6,66666666666667;;;;;;0;inf;72,25;inf;h;;from metabolic clearance ratio;500;;mg;PO;(S-0,T-12,R-8);h;MD BID (4 days);MD;;Klacid Pro;;;;;;;
362;Okudaira 2007;https://www,ncbi,nlm,nih,gov/pubmed/17585116;EM 2 with Perpetrator (Erythromycin);Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,16;arith, mean;0,45;arith, SD;0,909090909;Approx, Avg;;;0;25;25;73;h;;"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized";200;;mg;PO;0-5-10,5-15-24-29-34,5-39;h;MD QID (2 days);MD;erythromycin;Erythrocin Dainippon Pharmaceutical Co;;150;;Fed;;;standardized light breakfast at 07:20am
363;Okudaira 2007;https://www,ncbi,nlm,nih,gov/pubmed/17585116;EM 4 with Perpetrator (Erythromycin);Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,69;arith, mean;0,8;arith, SD;1,2;Approx, Avg;;;0;25;73;145;h;;"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized";200;;mg;PO;0-5-10,5-15-24-29-34,5-39-48-53-58,5-63-72-77-82,5-87;h;MD QID (4 days);MD;erythromycin;Erythrocin Dainippon Pharmaceutical Co;;150;;Fed;;;standardized light breakfast at 07:20am
364;Okudaira 2007;https://www,ncbi,nlm,nih,gov/pubmed/17585116;EM 7 with Perpetrator (Erythromycin);Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,69;arith, mean;0,7;arith, SD;1,172727273;Approx, Avg;;;0;25;145;inf;h;;"Reported values in the paper are dose-normalized; the values given here refer to the absolute doses and are not dose-normalized";200;;mg;PO;0-5-10,5-15-24-29-34,5-39-48-53-58,5-63-72-77-82,5-87-96-101-106,5-111-120-125-130,5-135-144-149-154,5-159;h;MD QID (7 days);MD;erythromycin;Erythrocin Dainippon Pharmaceutical Co;;150;;Fed;;;standardized light breakfast at 07:20am
366;Olkkola 1993;https://www,ncbi,nlm,nih,gov/pubmed/8453848;po with Perpetrator (Erythromycin);Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;4,067402;geo, Mean;0,71-12,0;Range;2,7;Approx, Avg;;;0;inf;128;inf;h;;Individual AUC ratios extracted from Fig, 5, the geometric mean value listed here as calculated based on the extracted values;500;;mg;PO;(S0-T8-R16)-126-136-144-152-160;h;MD TID (7 days);three times a day;erythromycin base;Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd,;;200;;;;;
368;Olkkola 1993;https://www,ncbi,nlm,nih,gov/pubmed/8453848;iv with Perpetrator (Erythromycin);Midazolam;Erythromycin;IV;PO;Mechanism_based_Inactivation;Plasma;1,961934;geo, Mean;1,30-2,48;Range;;;;;0;inf;128;inf;h;;Individual AUC ratios extracted from Fig, 5, the geometric mean value listed here as calculated based on the extracted values;500;;mg;PO;(S0-T8-R16)-126-136-144-152-160;h;MD TID (7 days);three times a day;erythromycin base;Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd,;;200;;;;;
370;Olkkola 1994;https://www,ncbi,nlm,nih,gov/pubmed/8181191;po with Perpetrator (Itraconazole);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;10,8;arith, mean;;;3,4;arith, Mean;;;0;inf;73;inf;h;;;200;;mg;PO;0-24-48-72;h;MD OD (4 days);MD;itraconazole;Sporanox, Orion;;;;Fasted;2;5;
371;Olkkola 1994;https://www,ncbi,nlm,nih,gov/pubmed/8181191;po with Perpetrator (Ketoconazole;Midazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;15,9;arith, mean;;;4,1;arith, Mean;;;0;inf;73;inf;h;;;400;;mg;PO;0-24-48-72;h;MD OD (4 days);MD;ketoconazole;Nizoral, Orion;;;;Fasted;2;5;
377;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 1 (po) with Perpetrator (Itraconazole);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;3,4;arith, mean;;;1,8;arith, Mean;;;0;inf;2;74;h;;;200;;mg;PO;0;h;SD;SD;;;;;;;;;
378;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 4 (iv) with Perpetrator (Itraconazole);Midazolam;Itraconazole;IV;PO;Reversible_Inhibition;Plasma;3,225806452;Approx, Avg;;;;;;;0;inf;74;122;h;;;200;;mg;PO;0-24-48-72;h;MD OD (4 days);MD;;;;;;;;;
379;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 6 (po) with Perpetrator (Itraconazole);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;6,6;arith, mean;;;2,5;arith, Mean;;;0;inf;122;inf;h;;;200;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;;;;;;;;;
380;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 1 (po) with Perpetrator (Fluconazole);Midazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;2,5;arith, mean;;;2,5;arith, Mean;;;0;inf;2;inf;h;;;400;;mg;PO;0;h;SD;MD;;;;;;;;;
381;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 4 (iv) with Perpetrator (Fluconazole);Midazolam;Fluconazole;IV;PO;Reversible_Inhibition;Plasma;2,040816327;Approx, Avg;;;;;;;0;inf;74;inf;h;;;400/200;;mg;PO;400: 0, 200: 24-48-72;h;MD OD (4 days);MD;;;;;;;;;
382;Olkkola 1996;https://www,ncbi,nlm,nih,gov/pubmed/8623953;day 6 (po) with Perpetrator (Fluconazole);Midazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;3,6;arith, mean;;;1,7;arith, Mean;;;0;inf;122;inf;h;;;400/200;;mg;PO;400: 0, 200: 24-48-72-96-120;h;MD OD (6 days);MD;;;;;;;;;
342;Link 2008;https://www,ncbi,nlm,nih,gov/pubmed/18537963;iv with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,655007949;Approx, Median;;;1,105960265;Approx, Median;;;0;inf;144;inf;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampicin;Rimactanﾮ, 600 mg coated tablet, Medika AG,;;;in the morning;;;;
391;Phimmasone 2001;https://www,ncbi,nlm,nih,gov/pubmed/11753266;with Perpetrator (Rifampicin);Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,55;arith, mean;;;;;;;0;inf;107;inf;h;1;;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);MD;rifampin;;;;in the evening;;;;
344;Link 2008;https://www,ncbi,nlm,nih,gov/pubmed/18537963;po with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,015549077;Approx, Median;;;0,034865293;Approx, Median;;;0;inf;144;inf;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD;rifampicin;Rimactanﾮ, 600 mg coated tablet, Medika AG,;;;in the morning;;;;
389;Phimmasone 2001;https://www,ncbi,nlm,nih,gov/pubmed/11753266;with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,51;arith, mean;;;;;;;0;inf;106;inf;h;1;;600;;mg;PO;0-24-48-72-96;h;MD OD (5 days);MD;rifampin;;;;in the evening;;;;
1098;Prueksaritanont 2017;https://www,ncbi,nlm,nih,gov/pubmed/27943276;Midazolam in microdosecocktail + Rifampin;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,94;Geom, mean;0,66 - 1,35;90% CI;1,3;Geom, mean;1,16 - 1,46;90% CI;0;inf;0;inf;h;1;Also available: ratio for AUC(0-last): geom, Mean (GMR) (90% CI) in pg*h/ml: 0,86 (0,62 - 1,20);600;;mg;PO;0;h;SD;SD;rifampin;USP 300 mg capsules;;;;;;;
396;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 0 after Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Plasma;1462;arith, mean;;;1,49;arith, mean;;;1321;inf;649;817;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
397;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 1 after Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Plasma;683;arith, mean;;;69,3;arith, mean;;;1321;inf;817;985;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
398;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 2 after Perpetrator (Rifampicin);Digoxin;Rifampicin;PO;PO;Induction;Plasma;977;arith, mean;;;87,6;arith, mean;;;1321;inf;985;1321;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
401;Saari 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580904;po with Perpetrator (Voriconazole);Midazolam;Voriconazole;PO;PO;;Plasma;9,85;geo, Mean;8,23-11,79;90% CI;3,56;geo, Mean;2,85-4,44;90% CI;0;inf;37;inf;h;;;400/200;;mg;PO;400mg: 0-12, 200mg: 24-36;h;MD BID (2 days), with first dose as loading dose;MD;voriconazole;Vfend tablet Pfizer;;150;The last dose of voriconazole was given at 8 AM with 150 mL of water;Fasted;11;5;
404;Saari 2006;https://www,ncbi,nlm,nih,gov/pubmed/16580904;iv with Perpetrator (Voriconazole);Midazolam;Voriconazole;IV;PO;;Plasma;3,61;geo, Mean;3,20-4,08;90% CI;;;;;0;inf;37;inf;h;;;400/200;;mg;PO;400mg: 0-12, 200mg: 24-36;h;MD BID (2 days), with first dose as loading dose;MD;voriconazole;Vfend tablet Pfizer;;150;The last dose of voriconazole was given at 8 AM with 150 mL of water;Fasted;11;5;
420;Swart 2002;https://www,ncbi,nlm,nih,gov/pubmed/11851636 ;day 10 Control with Perpetrator (Erythromycin);Midazolam;Erythromycin;IV;PO;Mechanism_based_Inactivation;Plasma;1,597786;geo, Mean;0,872-3,0;Range;;;;;0;inf;96;inf;h;;according to the methods section, AUC was calculated, but data are not given in text or tables,;500;;mg;PO;(S0-T6-R20);h;MD QID (5 days);erythromycin was taken 4 times per day, but timing was not specified, A fixed dose interval oh tau=6h was assumed, Midazolam and lignocaine were co-administered with erythromycin,;;Capsule;;200;2x 100-mg itraconazole capsules with coated sugar spheres;;;;
392;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 0 after Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;123;arith, mean;;;162;arith, mean;;;1320;inf;648;816;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
424;Templeton 2010;https://www,ncbi,nlm,nih,gov/pubmed/20739919;with Perpetrator (Itraconazole @ 50 mg);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;2;arith, Mean;0,6;arith, SD;;;;;0;inf;4;inf;h;;;50;;mg;PO;0;h;SD;SD;;Oral solution;;;;Fasted;;0,5;wrt, administration of midazolam
425;Templeton 2010;https://www,ncbi,nlm,nih,gov/pubmed/20739919;with Perpetrator (Itraconazole @ 200 mg);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;4,7;arith, Mean;1,4;arith, SD;;;;;0;inf;4;inf;h;;;200;;mg;PO;0;h;SD;SD;;Oral solution;;;;Fasted;;0,5;wrt, administration of midazolam
426;Templeton 2010;https://www,ncbi,nlm,nih,gov/pubmed/20739919;with Perpetrator (Itraconazole @ 400 mg);Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;5,4;arith, Mean;1,5;arith, SD;;;;;0;inf;4;inf;h;;;400;;mg;PO;0;h;SD;SD;;Oral solution;;;;Fasted;;0,5;wrt, administration of midazolam
428;Tham 2006;https://www,ncbi,nlm,nih,gov/pubmed/16628140;with Perpetrator (Ketoconazole 50 mg);Midazolam;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;1,588235294;Approx, Avg;;;;;;;0;inf;47;inf;h;;;200;;mg;PO;0-12-24-36-48-60;h;MD BID (3 days);MD;ketoconazole;Janssen Cilag;;;at 8am and 8pm;;;;
469;Yeates 1996;http://www,ncbi,nlm,nih,gov/pubmed/8880291;with Perpetrator (Clarithromycin);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;3,571572095;Approx, Avg;;;2,439979191;Approx, CmaxR;;;0;inf;97,5;inf;h;;;250;;mg;PO;(S-0,T-12-R-10);h;MD BID (5 days);MD BID;;Klacid tabelts;;;Kacid tablets from Abbot;Fasted;;2;
471;Zimmermann 1996;https://www,ncbi,nlm,nih,gov/pubmed/8720318;with Perpetrator (Erythromycin);Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;3,813719284;Approx, Avg;;;2,711438346;Approx, CmaxR;;;0;inf;97,5;inf;h;;;500;;mg;PO;(S-0,T-8-R-15);h;MD TID (3 days);MD TID;;Zithromax;;100;Zitrhromax Pfizer;Fasted;10;3,5;
571;Iwamoto 2008;https://www,ncbi,nlm,nih,gov/pubmed/18513146;Study I, Period 2 (ATV treatment);Raltegravir;Atazanavir;PO;PO;Reversible_Inhibition;Plasma;1,72;geo, Mean;1,47-2,02;90% CI;1,53;geo, Mean;1,11-2,12;90% CI;0;inf;144;inf;h;;;400;;mg;PO;0-24-48-72-96-120-144-168-192;h;MD OD (9 days);MD QD;;;;;;Fed;;;
573;Neely 2010;https://www,ncbi,nlm,nih,gov/pubmed/20823282;Study arm B (Raltegravir 400mg OD + Atazanavir 400 mg OD);Raltegravir;Atazanavir;PO;PO;Reversible_Inhibition;Plasma;1,72;geo, Mean;0,79-3,75;90% CI;1,37;geo, Mean;0,62-3,02;90% CI;168;180;168;192;h;;;400;;mg;PO;0-24-48-72-96-120-144-168;h;MD OD (8 days);MD QD;;;;;Capsule;Semifasted;1;2;
575;Krishna 2016;https://www,ncbi,nlm,nih,gov/pubmed/27696440;Period 2, Day 7 (1200 mg raltegravir SD with OD doses of 400 mg ATV);Raltegravir;Atazanavir;PO;PO;Reversible_Inhibition;Plasma;1,67;geo, Mean;1,34-2,10;90% CI;1,16;geo, Mean;1,01-1,33;90% CI;0;inf;144;inf;h;;;400;;mg;PO;0-24-48-72-96-120-144-168-192;h;MD OD (9 days);MD QD;;;;;;Fed;;;standard moderate-fat breakfast
579;Zhu 2010;https://www,ncbi,nlm,nih,gov/pubmed/21149917;Raltegravir 400 mg twice daily plus atazanavir 300 mg twice daily;Raltegravir;Atazanavir;PO;PO;Reversible_Inhibition;Plasma;1536;geo, Mean;1,135-2,081;90% CI;1394;geo, Mean;0,990-1,964;90% CI;96;108;600;612;h;;;400;;mg;PO;288-300-312-324-336-348-360-372-384-396-408-420-432-444-456-468-480-492-504-516-528-540-552-564-576-588-600-612;h;MD BID (14 days);MD BID;Atazanavir sulfate;Reyatazﾮ Bristol-Myers Squibb;;;;Fed;;;light meal (277 kcal)
642;Kasichayanula 2013a;https://www,ncbi,nlm,nih,gov/pubmed/23061428;Study 2: with Perpetrator (Mefenamic Acid);Dapagliflozin;Mefenamic Acid;PO;PO;Reversible_Inhibition;Plasma;1,51;geo, Mean;1,44-1,58;90% CI;1,13;geo, Mean;1,03-1,24;90% CI;0;inf;24;inf;h;;;500 / 250;;mg;PO;0-6-12-18-24-(S-30,T-6,R-11);h;MD QID (4 days), with first dose ad loading dose;first dose 500, then 250 mg;;;;;;Fed/Fasted;;;24h hour dose fasted, other fed
643;Kasichayanula 2013a;https://www,ncbi,nlm,nih,gov/pubmed/23061428;Study 1: with Perpetrator (Rifampicin);Dapagliflozin;Rifampicin;PO;PO;Induction;Plasma;0,78;geo, Mean;0,73-0,83;90% CI;0,93;geo, Mean;0,78-1,11;90% CI;0;inf;120;inf;h;1;;600;;mg;PO;0-24-48-72-96-120-144-168-192-216;h;MD OD (10 days);OD;;;;;;;;;
757;Phillips 1986;https://www,ncbi,nlm,nih,gov/pubmed/3771812;Triazolam after 3 days of erythromycin;Triazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;2,059701;Approx, Avg;;;1,464286;Approx, Avg;;;0;inf;64;inf;h;;Time of triazolam administration relative to erythromycin administration not reported, both drugs were assumed to be taken at the same time;333;;mg;PO;0-8-16-24-32-40-48-56-64;h;MD TID (3 days);MD TID;;E-Mycin;;;;;;;
761;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Grapefruit coadmin sequential;Alfentanil;Grapefruit juice;IV;PO;;Plasma;1;Geom, mean;0,9-1,0;90% CI;;;;;0;inf;0;inf;h;;;8;;oz;PO;0;h;SD;;;;;;;;;;
762;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Ketoconazole coadmin sequential;Alfentanil;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;2,4;Geom, mean;;;;;;;0;inf;60;inf;h;;calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control);400;;mg;PO;0-24-48-72;h;MD OD (4 days);MD QD;;;;;;;;;
763;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Rifampin coadmin sequential;Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,4;Geom, mean;0,3-0,4;90% CI;;;;;0;24;108;132;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD QD;;;;;;;;;
765;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Grapefruit coadmin simultaneous;Alfentanil;Grapefruit juice;IV;PO;;Plasma;1,2;Geom, mean;1,1-1,2;90% CI;;;;;0;inf;24;inf;h;;;8;;oz;PO;0;h;SD;;;;;;;;;;
766;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Ketoconazole coadmin simultaneous;Alfentanil;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;2,5;Geom, mean;;;;;;;0;inf;84;inf;h;;calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control);400;;mg;PO;0-24-48-72;h;MD OD (4 days);MD QD;;;;;;;;;
767;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil IV Rifampin coadmin simultaneous;Alfentanil;Rifampicin;IV;PO;Induction;Plasma;0,4;Geom, mean;0,2-0,7;90% CI;;;;;24;inf;132;inf;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD QD;;;;;;;;;
769;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Grapefruit coadmin sequential;Alfentanil;Grapefruit juice;PO;PO;;Plasma;1,7;Geom, mean;1,5-1,7;90% CI;;;;;0;inf;0;inf;h;;;8;;oz;PO;0;h;SD;;;;;;;;;;
770;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Ketoconazole coadmin sequential;Alfentanil;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;2,3;Geom, mean;;;;;;;0;inf;63;inf;h;;calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control);400;;mg;PO;0-24-48-72;h;MD OD (4 days);MD QD;;;;;;;;;
771;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Rifampin coadmin sequential;Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,06;Geom, mean;0,05-0,07;90% CI;;;;;0;21;111;132;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD QD;;;;;;;;;
773;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Grapefruit coadmin simultaneous;Alfentanil;Grapefruit juice;PO;PO;;Plasma;2,2;Geom, mean;1,9-2,5;90% CI;;;;;0;inf;21;inf;h;;;8;;oz;PO;0;h;SD;;;;;;;;;;
774;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Ketoconazole coadmin simultaneous;Alfentanil;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;3;Geom, mean;;;;;;;0;inf;84;inf;h;;calculated as reported AUCR*Dose(under Keto coadmin)/Dose(control);400;;mg;PO;0-24-48-72;h;MD OD (4 days);MD QD;;;;;;;;;
775;Kharasch 2011b;https://www,ncbi,nlm,nih,gov/pmc/articles/PMC3584707/;Alfentanil PO Rifampin coadmin simultaneous;Alfentanil;Rifampicin;PO;PO;Induction;Plasma;0,06;Geom, mean;0,01-0,22;90% CI;;;;;21;inf;132;inf;h;1;;600;;mg;PO;0-24-48-72-96-120;h;MD OD (6 days);MD QD;;;;;;;;;
777;Yasui 1996;https://www,ncbi,nlm,nih,gov/pubmed/8646822;Treatment with erythromycin;Alprazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;2,471616;Approx, Avg;;;1,183333;Approx, Avg;;;0;inf;170;inf;h;;;400;;mg;PO;0-8-16-24-32-40-48-56-64-72-80-88-96-104-112-120-128-136-144-152-160-168-176-184-192-200-208-216-224-232;h;MD TID (10 days);MD TID;;Ilotysin;;;;Fasted;overnight;;
779;Bartkowski 1989;https://www,ncbi,nlm,nih,gov/pubmed/2501060;Treatment Day 1;Alfentanil;Erythromycin;IV;PO;Mechanism_based_Inactivation;Serum;1,026178;Geom, mean;1,204995;Geom, SD;;;;;0;inf;1,5;inf;h;;Individual AUCinf calculated as Dose/CL, Individual CL values are given in Tab, 1, Individual values subsequently used to calculate Geom, Mean and geom, SD,;500;;mg;PO;0;h;SD;SD;;E-Mycin;;;;Fasted;overnight;;
780;Bartkowski 1989;https://www,ncbi,nlm,nih,gov/pubmed/2501060;Treatment Day 7;Alfentanil;Erythromycin;IV;PO;Mechanism_based_Inactivation;Serum;1,461094;Geom, mean;1,312773;Geom, SD;;;;;0;inf;145,5;inf;h;;Individual AUCinf calculated as Dose/CL, Individual CL values are given in Tab, 1, Individual values subsequently used to calculate Geom, Mean and geom, SD,;500;;mg;PO;0-12-24-36-48-60-72-84-96-108-120-132-144;h;MD BID (6 days);MD BID;;E-Mycin;;;;Fasted;overnight;;
781;Greenblatt 1998a;https://www,ncbi,nlm,nih,gov/pubmed/9757151;Triazolam + Erythromycin (Trial D);Triazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;3,65;Arith, Mean;0,42;Arith, SEM;1768;Approx, Avg;;;0;inf;25;inf;h;;;500;;mg;PO;0-8-24-33;h;MD OD (2 days);MD, day1: 8 am,, 4 pm,, day2: 8 am,, 5 pm,;;capsules;;;double blind design, medication were packaged identically in opaque capsules;Fed;;4;Light breakfast
801;Kharasch 2012;https://www,ncbi,nlm,nih,gov/pubmed/22398970;Alfentanil PO + efavirenz;Alfentanil;Efavirenz;PO;PO;Induction;Plasma;0,22;Geom, mean;0,16-0,30;90% CI;0,4285714;Approx, Avg;;;0;inf;336,5;inf;h;;Administration time of alfenatil relative to efavirenz administration was not reported, here, it was assumed that alfentanil was dosed 30 min after efavirenz administration;600;;mg;PO;0-24-48-72-96-120-144-168-192-216-240-264-288-312-336-360-384-408-432-456;h;MD OD (19 days);MD QD;;;;;;;;;
803;Kharasch 2012;https://www,ncbi,nlm,nih,gov/pubmed/22398970;Alfentanil IV + efavirenz;Alfentanil;Efavirenz;IV;PO;Induction;Plasma;0,54;Geom, mean;0,47-0,62;90% CI;1,097826;Approx, Avg;;;0;inf;360,5;inf;h;;Administration time of alfenatil relative to efavirenz administration was not reported, here, it was assumed that alfentanil was dosed 30 min after efavirenz administration;600;;mg;PO;0-24-48-72-96-120-144-168-192-216-240-264-288-312-336-360-384-408-432-456;h;MD OD (19 days);MD QD;;;;;;;;;
828;Carls 2014;https://www,ncbi,nlm,nih,gov/pubmed/25139487;Midazolam + 250 mg erythromycin ;Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,71781;Approx, Avg;;;;;;;2;4;3;5;h;;;250;;mg;PO;0;h;SD;SD;;Erythromycin-ratiopharmﾮ 500 mg filmtablets containing 694 mg erythromycinstearate;;;;;;;
829;Carls 2014;https://www,ncbi,nlm,nih,gov/pubmed/25139487;Midazolam + 1000 mg erythromycin ;Midazolam;Erythromycin;PO;PO;Mechanism_based_Inactivation;Plasma;4,99118;Approx, Avg;;;;;;;2;4;3;5;h;;;1000;;mg;PO;0;h;SD;SD;;Erythromycin-ratiopharmﾮ 500 mg filmtablets containing 694 mg erythromycinstearate;;;;;;;
1001;Schmider 1999;https://www,ncbi,nlm,nih,gov/pubmed/10634135;Alprazolam + Rifampin;Alprazolam;Rifampicin;PO;PO;Induction;Plasma;0,117258464;Approx, Avg;;;0,638157895;Approx, CmaxR;;;0;inf;96;inf;h;1;Administration time of alprazolam relative to rifampin administration was not reported, here, it was assumed that alprazolam was administered 24h after the last rifampin administration;450;;mg;;S0-T24-R4;h;MD OD (4 days);MD QD;;;;;;;;;
1002;Schmider 1999;https://www,ncbi,nlm,nih,gov/pubmed/10634135;Alprazolam + Ketoconazole;Alprazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;1,759702725;Approx, Avg;;;1,078947368;Approx, CmaxR;;;0;inf;48;inf;h;;Administration time of alprazolam relative to ketoconazole administration was not reported, here, it was assumed that alprazolam was administered 12h after the last ketoconazole administration;200;;mg;;S0-T12-R4;h;MD BID (2 days);MD BID;;;;;;;;;
1004;Villikka 1997;https://www,ncbi,nlm,nih,gov/pubmed/9024169;Treatment arm (pretreatment with rifampin, 600 mg, 5 days);Triazolam;Rifampicin;PO;PO;Induction;Plasma;51;Arith, Mean;0,032-0,071;95%CI;0,124137931;Approx, CmaxR;;;0;inf;113;inf;h;1;AUC ratio from Tab, 1;600;;mg;PO;S0-T24-R5;h;MD OD (5 days);MD, QD (at 8 pm);;two 300 mg Rimapen capsules, Orion Pharmaceutical Company Ltd,, Espoo, Finland;;;;;;;
1026;Yasui 1998;https://www,ncbi,nlm,nih,gov/pubmed/9784084;Alprazolam with itraconazole;Alprazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;2,662698413;Approx, Avg;;;1,286821705;Approx, CmaxR;;;0;inf;73;inf;h;;;200;;mg;PO;(S0-T24-R6);h;MD OD (6 days);MD, QD (at 8 am);;capsule formulation (Itrizole, Janssen-Kyowa Co, Ltd, Tokyo, Japan);;;;;;;
1028;Varhe 1994;https://www,ncbi,nlm,nih,gov/pubmed/7995001;Triazolam with ketoconazole;Triazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;20,06386189;Geom, Mean;5,00-71,1;Range;3,107487126;Geom, Mean;1,46-5,1;Range;0;inf;73;inf;h;;AUC and Cmax ratios calculated based on individual data listed in Tab, 2;400;;mg;;S0-T24-R4;h;MD OD (4 days);MD, QD;;Nizoral, Orion, Helsinki, Finland;;;;;;;The use of alcohol, coffee, tea, and cola was not allowed during the testdays
1029;Varhe 1994;https://www,ncbi,nlm,nih,gov/pubmed/7995001;Triazolam with Itraconazole;Triazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;19,02874555;Geom, Mean;7,24-181;Range;2,685447833;Geom, Mean;1,17-10,4;Range;0;inf;73;inf;h;;AUC and Cmax ratios calculated based on individual data listed in Tab, 2;200;;mg;;S0-T24-R4;h;MD OD (4 days);MD, QD;;Sporanox, Orion;;;;;;;The use of alcohol, coffee, tea, and cola was not allowed during the testdays
1078;Neuvonen 1996;https://www,ncbi,nlm,nih,gov/pubmed/8841155;Treatment phase (triazolam + ITZ simultaneously);Triazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;3,11;Arith, mean;;;1,41;arith, Mean;;;0;inf;0;inf;h;;AUC and Cmax ratio taken from percentage change listed in Tab, 1;200;;mg;PO;0;h;SD;SD;;Sporanox, Janssen Pharma, Beerse, Belgium;;150;;fasted;3;4;itraconazole dose was taken 3 h after lunch, the use of alcohol, tea, coffee, and cola was not allowed during the test days
1079;Neuvonen 1996;https://www,ncbi,nlm,nih,gov/pubmed/8841155;Treatment phase (triazolam + ITZ 3 hr before);Triazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;4,79;Arith, mean;;;1,76;arith, Mean;;;0;inf;3;inf;h;;AUC and Cmax ratio taken from percentage change listed in Tab, 1;200;;mg;PO;0;h;SD;SD;;Sporanox, Janssen Pharma, Beerse, Belgium;;150;;Triazola, fasted, ITZ fed;3;;itraconazole dose was taken after lunch, the use of alcohol, tea, coffee, and cola was not allowed during the test days
1080;Neuvonen 1996;https://www,ncbi,nlm,nih,gov/pubmed/8841155;Treatment phase (triazolam + ITZ 12 hr before);Triazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;4,63;Arith, mean;;;1,76;arith, Mean;;;0;inf;12;inf;h;;AUC and Cmax ratio taken from percentage change listed in Tab, 1;200;;mg;PO;0;h;SD;SD;;Sporanox, Janssen Pharma, Beerse, Belgium;;150;;Triazola, fasted, ITZ fed;3;;itraconazole dose was taken with a snack, the use of alcohol, tea, coffee, and cola was not allowed during the test days
1081;Neuvonen 1996;https://www,ncbi,nlm,nih,gov/pubmed/8841155;Treatment phase (triazolam + ITZ 24 hr before);Triazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;3,82;Arith, mean;;;1,71;arith, Mean;;;0;inf;24;inf;h;;AUC and Cmax ratio taken from percentage change listed in Tab, 1;200;;mg;PO;0;h;SD;SD;;Sporanox, Janssen Pharma, Beerse, Belgium;;150;;Triazola, fasted, ITZ fed;3;;i
1087;Lam 2003;https://www,ncbi,nlm,nih,gov/pubmed/14551182;Midazolam after Ketoconazole;Midazolam;Ketoconazole;PO;PO;Reversible_Inhibition;Plasma;8,72;mean percent change;5,96;SD;3,68;mean percent change;2,22;SD;0;inf;265;inf;h;;;200;;mg;;(S0-T24-R12);h;MD OD (12 days);MD, once daily;ketoconazole;;;;;;;;
1089;Lam 2003;https://www,ncbi,nlm,nih,gov/pubmed/14551182;Midazolam after Fluvoxamine;Midazolam;Fluvoxamine;PO;PO;Reversible_Inhibition;Plasma;1,66;mean percent change;0,8;SD;1,63;mean percent change;1,07;SD;0;inf;265;inf;h;;;50/100;;mg;;(S0-T12-R23);h;MD OD (12 days), titrated from 50 mg BID to 100 mg BID administered for 6 days;MD, twice daily, titrated from 50 mg bid to 100 mg bid 100 mg bid administered for 6 days;fluvoxamine;;;;;;;;
1091;Shin 2013;https://www,ncbi,nlm,nih,gov/pubmed/23784264;CYP3A4 inhibited phase (Midazolam + ketoconazole);Midazolam;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;2,89;geom, Mean (GMR);2,57 - 3,25;90% CI;;;;;0;inf;73;inf;h;1;also available: Ratio of geom, Mean (90% CI) of CL in L/h: 0,35 (0,32 - 0,37);400;;mg;PO;(S0-T24-R4);h;MD OD (4 days);MD, q,d, for 4 days;ketoconazole (400-mg tablet);Spike, Choong Wae Pharm, Seoul, Korea;;;;;;;
393;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 1 after Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;383;arith, mean;;;403;arith, mean;;;1320;inf;816;984;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
1094;Shin 2016;https://www,ncbi,nlm,nih,gov/pubmed/27317471;Midazolam + ketoconazole;Midazolam;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;4,77;geom, Mean (GMR);4,52 - 5,03;90% CI;1,45;geom, Mean (GMR);1,38 - 1,53;90% CI;0;inf;73;inf;h;1;;400;;mg;;(S0-T24-R4);h;MD OD (4 days);MD, q,d, for 4 days;ketoconazole;Spike, Choongwae Pharma Co,, Seoul, Korea;;;;;;;
394;Reitman 2011;https://www,ncbi,nlm,nih,gov/pubmed/21191377;Week 2 after Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;815;arith, mean;;;731;arith, mean;;;1320;inf;984;1320;h;1;Week 4 as Control;600;;mg;PO;S0-T24-R28;h;MD OD (28 days);;;Rifadin (2x 300mg);;;Rifadin 2x 300 mg (Merrel);Fasted;;;
1097;Prueksaritanont 2017;https://www,ncbi,nlm,nih,gov/pubmed/27943276;Midazolam in microdosecocktail + Itraconazole;Midazolam;Itraconazole;PO;PO;Reversible_Inhibition;Plasma;7,04;Geom, mean;4,58 - 10,81;90% CI;3,71;Geom, mean;3,38 - 4,09;90% CI;0;inf;72;inf;h;;Also available: ratio for AUC(0-last): geom, Mean (GMR) (90% CI) in pg*h/ml: 6,80 (4,52 - 10,23);200;;mg;PO;(S0-T24-R5);h;MD OD (5 days);MD, q,d, for 5 days;itraconazole;10 mg/mL oral solution;;;;;;;
1092;Shin 2013;https://www,ncbi,nlm,nih,gov/pubmed/23784264;CYP3A4 induced phase (Midazolam + rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;1,15;geom, Mean (GMR);1,025 - 1,275;90% CI;;;;;0;inf;216;inf;h;2,5;Cave! Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control), Also avaiable: Ratio of geom, Mean (90% CI) of CL in L/h: 2,19 (1,99 - 2,40);600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;rifampicin (600-mg tablet);Rifodex, Chong Kun Dang Pharmaceutical, Seoul, Korea;;;;;;;
1099;Prueksaritanont 2017;https://www,ncbi,nlm,nih,gov/pubmed/27943276;Midazolam in microdosecocktail + Clarithromycin;Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;4,84;Geom, mean;3,21 - 7,29;90% CI;2,69;Geom, mean;2,47 - 2,93 ;90% CI;0;inf;72;inf;h;;Also available: ratio for AUC(0-last): geom, Mean (GMR) (90% CI) in pg*h/ml: 4,71 (3,20 - 6,96);500;;mg;PO;(S0-T12-R10);h;MD BID (5 days);MD, b,i,d, (approx, every 12 h) for 5 days;clarithromycin;USP 500 mg tablets;;;;;;;
1102;Greenblatt 1998a;https://www,ncbi,nlm,nih,gov/pubmed/9757151;Triazolam + Clarithromycin (Trial E);Triazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;5,06;arithm, Mean;0,44;Arith, SEM;1968;Approx, Avg;;;0;inf;25;inf;h;;;500;;mg;PO;0-8-24-33;h;MD OD (2 days);MD, day1: 8 am,, 4 pm,, day2: 8 am,, 5 pm,;;capsules;;;double blind design, medication were packaged identically in opaque capsules;fed;;4;Light breakfast
1104;Fleishaker 1994;https://www,ncbi,nlm,nih,gov/pubmed/8005185;Alprazolam + fluvoxamine;Alprazolam;Fluvoxamine;PO;PO;Reversible_Inhibition;Plasma;1,255144033;Approx, Avg;;;1,176923077;Approx, CmaxR;;;0;5;144;149;h;;Measurement documented with day 1,  actually is day 7 of study period;50/100;;mg;PO;S0-T24-R7;h;MD OD (10 days), 50 mg day 1-3, then 100 mg;MD, 50 mg qd days 1-3, 100 mg qd days 4 -7;fluvoxamine maleate;oral capsules;;;for days 4-7: subjects took two 50 mg fluvoxamine maleate capsules;fed;;;The subjects ate standard meals at 07,00, 12,00, 18,00, and 22,00 h on all study days,
1106;Fleishaker 1994;https://www,ncbi,nlm,nih,gov/pubmed/8005185;Fluvoxamine + alprazolam;Fluvoxamine;Alprazolam;PO;PO;;Plasma;0,920731707;Approx, Avg;;;0,962790698;Approx, CmaxR;;;0;inf;0;inf;h;;Measurement on day 1;1;;mg;PO;144-149-154-159-168-173-178-183-192-197-202-207-216-221-226-231;h;MD QID (4 days);MD, 4 times daily for 4 days (days 7-10 of the study period);alprazolam;oral tablet;;;;fed;;;The subjects ate standard meals at 07,00, 12,00, 18,00, and 22,00 h on all study days,
1108;Backman 1994;https://www,ncbi,nlm,nih,gov/pubmed/8198928;Midazolam with verapamil;Midazolam;Verapamil;PO;PO;Mechanism_based_Inactivation;Plasma;2,916666667;Arith, mean;;;1,969230769;Arith, mean;;;0;inf;25;inf;h;;;80;;mg;PO;S0-T8-R5;h;MD TID (2 days);MD, day1: 14:30, 22:30, day2: 6:30, 14:30, 22:30;verpamil;Verpamil 40 mg tabl,, Orion Pharmaceutical Company Ltd;;;;;;;
1111;Wang 2005;https://ascpt,onlinelibrary,wiley,com/doi/abs/10,1016/j,clpt,2004,11,014;Midazolam after VER treatment;Midazolam;Verapamil;IV;PO;Mechanism_based_Inactivation;Plasma;1,452380952;Arith, mean;;;;;;;0;24;168;192;h;;AUCR was calculated with CLiv values;240;;mg;;S0-T24-R7;h;MD OD (7 days);MD;verapamil;verapamil (SR, 240 mg qd,);;;;;;;
1113;Fleishaker 1994;https://www,ncbi,nlm,nih,gov/pubmed/8005185;Alprazolam + fluvoxamine (day 10);Alprazolam;Fluvoxamine;PO;PO;Reversible_Inhibition;Plasma;1,963137996;Approx, Avg;;;1,861940466;Approx, CmaxR;;;72;96;216;240;h;;AUCratio and Cmax ratio also available for Day1;50/100;;mg;PO;S0-T24-R10;h;MD OD (10 days), 50 mg day 1-3, then 100 mg;MD, QD;fluvoxamin maleate;;;;;fed;;;The subjects ate standard meals at 07,00, 12,00, 18,00, and 22,00 h on all study days,
1114;Fleishaker 1994;https://www,ncbi,nlm,nih,gov/pubmed/8005185;Fluvoxamine + alprazolam (day 10);Fluvoxamine;Alprazolam;PO;PO;;Plasma;0,761066969;Approx, Avg;;;0,787512588;Approx, CmaxR;;;0;216;0;216;h;;Measurement on day 10;1;;mg;PO;144-149-154-159-168-173-178-183-192-197-202-207-216-221-226-231;h;MD QID (4 days);MD, 4 times daily for 4 days (days 7-10 of the study period);alprazolam;oral tablet;;;;fed;;;The subjects ate standard meals at 07,00, 12,00, 18,00, and 22,00 h on all study days,
1116;Wang 2005;https://ascpt,onlinelibrary,wiley,com/doi/abs/10,1016/j,clpt,2004,11,014;Midazolam after VER treatment;Midazolam;Verapamil;PO;PO;Mechanism_based_Inactivation;Plasma;3,505617978;Arith, mean;;;;;;;24;inf;192;inf;h;;AUCR was calculated with CLpo values;240;;mg;;S0-T24-R7;h;MD OD (7 days);MD;verapamil;verapamil (SR, 240 mg qd,);;;;;;;
1095;Shin 2016;https://www,ncbi,nlm,nih,gov/pubmed/27317471;Midazolam + rifampicin;Midazolam;Rifampicin;IV;PO;Induction;Plasma;1225;geom, Mean (GMR);1,15 - 1,325;90% CI;1775;geom, Mean (GMR);1,7 - 1,9;90% CI;0;inf;216;inf;h;2,5;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control),;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;rifampicin;Rifodex, Chong Kun Dang Pharmaceutical, Seoul, Korea;;;;;;;
422;Szalat 2007;https://www,ncbi,nlm,nih,gov/pubmed/17553741;with Perpetrator (Rifampicin);Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,579467114;Approx, Avg;;;;;;;0;inf;132;inf;h;1;;600;;mg;PO;0-24-48-72-96-120-144;h;MD OD (7 days);MD;rifampicin;rifampicin (Sandoz GmbH);;;;;;;
2004;van Dyk 2018;https://www,ncbi,nlm,nih,gov/pubmed/29572563;Midazolam in Caucasian following 3d of Clarithromycin (between day 12 and 14);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,9;geom, Mean;1,5, 2,3;95% CI;1,75;Approx, CmaxR;;;0;6;324;330;h;;"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in ﾵg/L/min: 2,0 (1,5, 2,4); Time adjusted to Time after first rifampicin dose";250;;mg;;S252-T12-R6;h;MD BID (3 days);MD, bd for a 3-day course;clarithromycin;Klacid Abbott Laboratories, NSW, Australia;;;;;;;
2005;van Dyk 2018;https://www,ncbi,nlm,nih,gov/pubmed/29572563;Midazolam in South Asian following 3d of Clarithromycin (between day 12 and 14);Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Plasma;1,5;geom, Mean;0,8, 2,2;95% CI;1,509090909;Approx, CmaxR;;;0;6;324;330;h;;"Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in ﾵg/L/min: 1,7 (1,0, 2,5); Time adjusted to Time after first rifampicin dose";250;;mg;;S252-T12-R6;h;MD BID (3 days);MD, bd for a 3-day course;clarithromycin;Klacid Abbott Laboratories, NSW, Australia;;;;;;;
2007;Kashuba 1998;https://www,ncbi,nlm,nih,gov/pubmed/9757149;Midazolam after Fluvoxamine;Midazolam;Fluvoxamine;IV;PO;Reversible_Inhibition;Plasma;1,5;Approx, Avg;;;;;;;0;inf;517;inf;h;;AUCR was calculated with CLiv values, 517 h is the mean of the two assessments (2 weeks / 4 weeks);50/100;;mg;PO;0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648;h;MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening;MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study,;fluvoxamine;50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga,);;;;;;;
2009;Gashaw 2003;https://www,ncbi,nlm,nih,gov/pubmed/?term=14586385;Alprazolam 10h concentration after Rifampin treatment (5 day rifampin treatment, day 7);Alprazolam;Rifampicin;PO;PO;Induction;Plasma;0,1793478;Approx, Avg;;;;;;;0;inf;100;436;h;1;AUCR was calculated with estimated CLoral values estimated from 1 plasma sample;450;;mg;PO;0-14-38-62-86;h;MD OD (5 days);MD, q,d, for 5 days;;Eremfat Fatol, Schiffweiler, Germany;;;;;;;
2010;Gashaw 2003;https://www,ncbi,nlm,nih,gov/pubmed/?term=14586385;Alprazolam 10h concentration after wash out (day 22);Alprazolam;Rifampicin;PO;PO;Induction;Plasma;0,9166667;Approx, Avg;;;;;;;0;inf;436;inf;h;1;AUCR was calculated with estimated CLoral values estimated from 1 plasma sample;450;;mg;PO;0-14-38-62-86;h;MD OD (5 days);MD, q,d, for 5 days;;Eremfat Fatol, Schiffweiler, Germany;;;;;;;
2012;Chen 2006;https://www,ncbi,nlm,nih,gov/pubmed/16842393;Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) overall;Midazolam;Fluvoxamine;IV;PO;Reversible_Inhibition;Plasma;1,490566038;Arith, mean;;;;;;;0;inf;336;inf;h;;AUCR was calculated with CLiv values;50/100;;mg;PO;0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648;h;MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening;MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study,;fluvoxamine;50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga,);;;;;;;
2014;Chen 2006;https://www,ncbi,nlm,nih,gov/pubmed/16842393;Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) Male;Midazolam;Fluvoxamine;IV;PO;Reversible_Inhibition;Plasma;1,617021277;Arith, mean;;;;;;;0;inf;336;inf;h;;AUCR was calculated with CLiv values;50/100;;mg;PO;0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648;h;MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening;MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study,;fluvoxamine;50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga,);;;;;;;
2016;Chen 2006;https://www,ncbi,nlm,nih,gov/pubmed/16842393;Midazolam post treatment with fluvoxamine (28 days of fluvoxamine) female;Midazolam;Fluvoxamine;IV;PO;Reversible_Inhibition;Plasma;1,372881356;Arith, mean;;;;;;;0;inf;336;inf;h;;AUCR was calculated with CLiv values;50/100;;mg;PO;0-24-48-58-72-82-96-106-120-130-144-154-168-178-192-202-216-226-240-250-264-274-288-298-312-322-336-346-360-370-384-394-408-418-432-442-456-466-480-490-504-514-528-538-552-562-576-586-600-610-624-634-648;h;MD BID (4 weeks), dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, then 50 mg in the morning and 100 mg in the evening;MD, twice a day for 4 weeks, dose titration to 150 mg/day over 7 days: 50 mg in the evening for 3 days, 50 mg in the morning and evening for the next 3 days, 50 mg in the morning and 100 mg in the evening for the remainder of the study,;fluvoxamine;50 mg fluvoxamine capsules (Luvox, lot number 87145, Solvay, Marietta, Ga,);;;;;;;
2018;Suzuki 2003;https://www,ncbi,nlm,nih,gov/pubmed/12698310;Alprazolam with fluvoxamine (Japanese);Alprazolam;Fluvoxamine;PO;PO;Reversible_Inhibition;Plasma;;;;;;;;;316 (N=13) / 324 (N=10);inf;316 (N=13) / 324 (N=10);inf;h;;;25 (N=19) / 50 (N=2) / 100 (N=2);;mg;PO;S0-T24-R14;h;MD OD (14 days);MD, The doses of FLV were 25 mg in 19 subjects, 50 mg in 2, and 100 mg in 2, FLV taken at 21:00 by all subjects,;fluvoxamine;oral formulation;;;;;;;
2025;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;iv Midazolam Female after clarithromycin;Midazolam;Clarithromycin;IV;PO;Mechanism_based_Inactivation;Whole Blood;3,6;GMR;2,8, 4,4;95% CI;1,206896552;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2026;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;iv Midazolam Male after clarithromycin;Midazolam;Clarithromycin;IV;PO;Mechanism_based_Inactivation;Whole Blood;2,9;GMR;2,0, 3,7;95% CI;1,118644068;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2027;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;iv Midazolam All after clarithromycin;Midazolam;Clarithromycin;IV;PO;Mechanism_based_Inactivation;Whole Blood;3,2;GMR;2,7, 3,8;95% CI;1,172413793;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2028;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;po Midazolam Female after clarithromycin;Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Whole Blood;8,2;GMR;4,8, 11,6;95% CI;2,833333333;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2029;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;po Midazolam Male after clarithromycin;Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Whole Blood;7,7;GMR;4,5, 11;95% CI;2,583333333;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2030;Quinney 2008;https://www,ncbi,nlm,nih,gov/pubmed/17635500;po Midazolam All after clarithromycin;Midazolam;Clarithromycin;PO;PO;Mechanism_based_Inactivation;Whole Blood;8;GMR;5,7, 10,2;95% CI;2,75;Approx, CmaxR;;;0;inf;146;inf;h;;;500;;mg;PO;S0-T12-R14;h;MD BID (7 days);MD, bid for 7 days;clarithromycin;;;;;;;;
2035;Kim 2018;https://www,ncbi,nlm,nih,gov/pubmed/28877336;Midazolam + Ketoconazole Male;Midazolam;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;2,89;geom, Mean (GMR);2,57 - 3,25;90% CI;;;;;0;inf;72;inf;h;1;;400;;mg;PO;S0-T24-R4;h;MD OD (4 days);MD, q,d, for 4 days;ketoconazole;oral formulation;;;;;;;
2002;van Dyk 2018;https://www,ncbi,nlm,nih,gov/pubmed/29572563;Midazolam in Caucasian following 7d of Rifampicin (between day 1 and 8);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,256410256;geom, Mean;0,208333333333333-0,333333333333333;95% CI;375;Approx, CmaxR;;;0;6;156;162;h;1;Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in ﾵg/L/min: 4,2 (3,2, 5,2);300;;mg;PO;S0-T24-R7;h;MD OD (7 days);MD, qd for a 7-day course each evening;rifampicin;Rifadin Sanofi, NSW, Australia;;;;;;;
2038;Kim 2018;https://www,ncbi,nlm,nih,gov/pubmed/28877336;Midazolam + Ketoconazole Female;Midazolam;Ketoconazole;IV;PO;Reversible_Inhibition;Plasma;4,77;geom, Mean (GMR);4,52 - 5,03;90% CI;;;;;0;inf;72;inf;h;1;;400;;mg;PO;S0-T24-R4;h;MD OD (4 days);MD, q,d, for 4 days;ketoconazole;oral formulation;;;;;;;
2003;van Dyk 2018;https://www,ncbi,nlm,nih,gov/pubmed/29572563;Midazolam in South Asian following 7d of Rifampicin (between day 1 and 8);Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,188679245;geom, Mean;0,15625-0,263157894736842;95% CI;0,218181818;Approx, CmaxR;;;0;6;156;162;h;1;Adjusted AUCratios (adjustment of different genotypes) are also available: AUC0-6 GMR with (95% CI)in ﾵg/L/min: 5,4 (3,8, 7,0);300;;mg;PO;S0-T24-R7;h;MD OD (7 days);MD, qd for a 7-day course each evening;rifampicin;Rifadin Sanofi, NSW, Australia;;;;;;;
2044;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam PO day 1;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,5905511;Geom, mean;;;;;;;0;6;12;18;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2045;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam IV day 1;Midazolam;Efavirenz;IV;PO;Induction;Plasma;0,78537735;Geom, mean;;;;;;;6;14;18;26;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2047;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam PO day 6;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,6141732;Geom, mean;;;;;;;0;6;132;138;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2048;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam IV day 6;Midazolam;Efavirenz;IV;PO;Induction;Plasma;0,7771226;Geom, mean;;;;;;;6;14;138;146;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2049;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam PO day 11;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,769685;Geom, mean;;;;;;;0;6;252;258;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2050;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam IV day 11;Midazolam;Efavirenz;IV;PO;Induction;Plasma;0,9375;Geom, mean;;;;;;;6;14;258;266;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2051;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam PO day 16;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,7480314;Geom, mean;;;;;;;0;6;372;378;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2052;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam IV day 16;Midazolam;Efavirenz;IV;PO;Induction;Plasma;0,8537735;Geom, mean;;;;;;;6;14;378;386;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2053;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam PO  day 22;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,8366141;Geom, mean;;;;;;;0;6;516;522;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
2054;Mikus 2017;https://www,ncbi,nlm,nih,gov/pubmed/28194792;Efavirenz + Midazolam IV  day 22;Midazolam;Efavirenz;IV;PO;Induction;Plasma;0,9221698;Geom, mean;;;;;;;6;14;522;530;h;;;400;;mg;PO;0;h;SD;;;;;;;;;;
197;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Itraconazole CYP3A5*1/*1;Midazolam;Itraconazole;IV;PO;Reversible_Inhibition;Plasma;2,272727273;Arith, mean;;;;;;;0;9999;72;9999;h;1;AUCR was calculated with CLiv values;200;;mg;PO;S0-T24-R4;h;MD OD (4 days);MD, q,d, for 4 days;;Sporanox capsules;;;;fasted;overnight;;
198;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Itraconazole CYP3A5*1/*3;Midazolam;Itraconazole;IV;PO;Reversible_Inhibition;Plasma;2,702702703;Arith, mean;;;;;;;0;9999;72;9999;h;1;AUCR was calculated with CLiv values;200;;mg;PO;S0-T24-R4;h;MD OD (4 days);MD, q,d, for 4 days;;Sporanox capsules;;;;fasted;overnight;;
199;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Itraconazole CYP3A5*3/*3;Midazolam;Itraconazole;IV;PO;Reversible_Inhibition;Plasma;3,333333333;Arith, mean;;;;;;;0;9999;72;9999;h;1;AUCR was calculated with CLiv values;200;;mg;PO;S0-T24-R4;h;MD OD (4 days);MD, q,d, for 4 days;;Sporanox capsules;;;;fasted;overnight;;
204;Wiesinger 2020;https://www,ncbi,nlm,nih,gov/pubmed/32275771;Weak-induction phase (RIF 10 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;539;GMR;0,491-0,592;90% CI;0,632653061;Approx, Avg;;;0;9999;180;444;h;1;;10;;mg;PO;S0-T24-R22;h;MD OD (22 days);MD, q,d, for 22 days;;Eremfat Sirup Suspension;;;;;;;
205;Wiesinger 2020;https://www,ncbi,nlm,nih,gov/pubmed/32275771;Strong-induction phase (RIF 600 mg);Midazolam;Rifampicin;PO;PO;Induction;Plasma;137;GMR;0,124-0,150;90% CI;0,18755102;Approx, Avg;;;0;9999;444;9999;h;1;;600;;mg;PO;S0-T24-R22;h;MD OD (22 days);MD, q,d, for 22 days;;Eremfat Tablet;;;;;;;
200;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Rifampicin CYP3A5*1/*1;Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,985221675;Arith, mean;;;;;;;0;9999;240;9999;h;2;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control), AUCR was calculated with CLiv values,;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;;Rifodex;;;;fasted;overnight;;
2041;Katzenmaier 2010;https://www,ncbi,nlm,nih,gov/pubmed/20680253;Midazolam + Efavirenz;Midazolam;Efavirenz;PO;PO;Induction;Plasma;0,1027;Approx, Avg;;;0,1806;Approx, Avg;;;0;12;336;340;h;;not mentioned in the paper, calculated from scanned aggregated data;400;;mg;PO;S0-T24-R14;h;MD OD (14 days);MD, q,d, for 14 days;Efavirenz;Sustiva;;;;;;;
201;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Rifampicin CYP3A5*1/*3;Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,819672131;Arith, mean;;;;;;;0;9999;240;9999;h;2;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control), AUCR was calculated with CLiv values,;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;;Rifodex;;;;fasted;overnight;;
202;Yu 2004;https://www,ncbi,nlm,nih,gov/pubmed/15289787;Treatment Rifampicin CYP3A5*3/*3;Midazolam;Rifampicin;IV;PO;Induction;Plasma;0,833333333;Arith, mean;;;;;;;0;9999;240;9999;h;2;Cave! Different dose treatment vs control, Ratios calculated as reported Ratio*Dose(under Rif coadmin)/Dose(control), AUCR was calculated with CLiv values,;600;;mg;PO;S0-T24-R10;h;MD OD (10 days);MD, q,d, for 10 days;;Rifodex;;;;fasted;overnight;;
2056;Barbarash 1988;https://www,ncbi,nlm,nih,gov/pubmed/3180898;Verapamil IV after 2 weeks of Rifampicin therapy;Verapamil;Rifampicin;IV;PO;Induction;Serum;0,81865285;Approx, Avg;;;;;;;0;inf;300;inf;h;1;;600;;mg;PO;S0-T24-R13;h;MD OD (13 days);1 oral dose every night;rifampin;oral formulation;;;;;;;
2058;Barbarash 1988;https://www,ncbi,nlm,nih,gov/pubmed/3180898;Verapamil PO after 2 weeks of Rifampicin therapy;Verapamil;Rifampicin;PO;PO;Induction;Serum;0,065110099;Approx, Avg;;;0,036960986;Approx, Avg;;;0;inf;348;inf;h;1;;600;;mg;PO;S0-T24-R15;h;MD OD (15 days);1 oral dose every night;rifampin;oral formulation;;;;;;;
1319;Greenblatt 1986;https://pubmed,ncbi,nlm,nih,gov/2935051/;300 mg QD Cimetidine, 5 mg Midazolam IV;Midazolam;Cimetidine;IV;PO;Reversible_Inhibition;Plasma;0,892561983;Approx, Avg;;;;;;;0;inf;24;inf;h;;calculated from CL values;300;;mg;;S0-T6-R8;h;MD QID (2 days);MD: QID (Day 1-2);;;;;;;;;Fasted on Day 2 (Subjects fasted 8h before and for 3h after MDZ dosing)
1321;Greenblatt 1986;https://pubmed,ncbi,nlm,nih,gov/2935051/;300 mg QD Cimetidine, 15 mg Midazolam PO;Midazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,132867133;Approx, Avg;;;1,055555556;Approx, Avg;;;0;inf;24;inf;h;;calculated from CL values;300;;mg;;S0-T6-R8;h;MD QID (2 days);MD: QID (Day 1-2);;;;;;;;;Fasted on Day 2 (Subjects fasted 8h before and for 3h after MDZ dosing)
1322;Martinez 1999;https://pubmed,ncbi,nlm,nih,gov/10223772/;800 mg Cimetidine, 7,5 mg Midazolam PO;Midazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,497333333;Approx, Avg;;;;;;;0;inf;0;inf;h;;;800;;mg;;0;h;SD;SD;;Sigma Chemical Co (Barcelona, Spain);;;;;;;
1324;Fee 1987;https://pubmed,ncbi,nlm,nih,gov/3802710/;400 mg BID Cimetidine, 15 mg Midazolam;Midazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,345637584;Approx, Avg;;;;;;;0;inf;25;inf;h;;;400;;mg;;0-12-24,5;h;MD: BID (1 day), OD (1 day);MD: BID (Day 1), OD (Day 2);;;;;;Fasted;overnight;;
1326;Salonen 1986;https://pubmed,ncbi,nlm,nih,gov/2939688/;400 mg Cimetidine, 15 mg Midazolam;Midazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,364877589;Approx, Avg;;;1,373211964;Approx, Avg;;;0;5;2;7;h;;;400;;mg;PO;0;h;SD;SD;;;;;;;;;
1328;Smith 1984;https://pubmed,ncbi,nlm,nih,gov/6478741/;IV 10 mg Verapamil + Cimetidine;Verapamil;Cimetidine;IV;PO;Reversible_Inhibition;Plasma;0,707692308;Approx, Avg;;;0,95923913;Approx, Avg;;;0;inf;168;inf;h;;;300;;mg;PO;S0-T6-R36;h;MD QID (9 days);MD QID (Day 1-9);;;;;;;;;
1330;Smith 1984;https://pubmed,ncbi,nlm,nih,gov/6478741/;PO 120 mg Verapamil + Cimetidine;Verapamil;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,369680851;Approx, Avg;;;1,133333333;Approx, Avg;;;0;inf;168;inf;h;;;300;;mg;PO;S0-T6-R36;h;MD QID (9 days);MD QID (Day 1-9);;;;;;;;;
1332;Abernethy 1983;https://pubmed,ncbi,nlm,nih,gov/6137021/;Alprazolam + Cimetidine;Alprazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,580952381;Approx, Avg;;;1,032258065;Approx, Avg;;;0;inf;12;inf;h;;calculated from CL values;300;;mg;PO;S0-T6-R4;h;MD QID (1 day);MD QID (Day 1);;;;;;Fasted;;;
1334;Abernethy 1983;https://pubmed,ncbi,nlm,nih,gov/6137021/;Triazolam + Cimetidine;Triazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,542857143;Approx, Avg;;;1,204081633;Approx, Avg;;;0;inf;12;inf;h;;;300;;mg;PO;S0-T6-R4;h;MD QID (1 day);MD QID (Day 1);;;;;;Fasted;;;
1336;Friedman 1988;https://pubmed,ncbi,nlm,nih,gov/3360971/;Triazolam + Cimetidine;Triazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,322981366;Approx, Avg;;;1,390180879;Approx, Avg;;;0;inf;24;inf;h;;;300;;mg;PO;S0-T6-R8;h;MD QID (2 days);MD QID (Day 1-2);;;;;;;;;Subjects fasted overnight before triazolam administration
1338;Cox 1986;https://pubmed,ncbi,nlm,nih,gov/3828486/;triazolam + cimetidine;Triazolam;Cimetidine;intraduodenal;PO;Reversible_Inhibition;Serum;1,545454545;Approx, Avg;;;1,350877193;Approx, Avg;;;0;inf;13;inf;h;;;300;;mg;PO;S0-T6-R4;h;MD QID (1 day);MD QID (Day 1);;oral liquid;;;;;;;Subjects were fasted for 12h prior to each triazolam treatment and for 4h after each treatment
1340;Pourbaix 1985;https://pubmed,ncbi,nlm,nih,gov/2864320/;Alprazolam + Cimetidine;Alprazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;1,727891156;Approx, Avg;;;1,818681319;Approx, Avg;;;168;240;336;408;h;;;200/400;;mg;;"(200mg): (S0-T5-R3)-(S24-T5-R3)-(S48-T5-R3)-(S72-T5-R3)-(S96-T5-R3)-(S120-T5-R3)-(S144-T5-R3)-(S168-T5-R3)-(S192-T5-R3)-(S216-T5-R3)-(S240-T5-R3)-(S264-T5-R3)-(S288-T5-R3)-(S312-T5-R3)-(S336-T5-R3)-(S360-T5-R3)-(S384-T5-R3); (400mg): S15-T24-R17";h;"(200mg): MD TID (17 days); (400mg): OD (17 days)";"(200mg): MD TID (Day 15-31); (400mg): OD (Day 15-31); 1 g/d";;;;;;;;;
1342;Pourbaix 1985;https://pubmed,ncbi,nlm,nih,gov/2864320/;Triazolam + Cimetidine;Triazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;2,201277955;Approx, Avg;;;1,510883483;Approx, Avg;;;144;168;327;351;h;;;200/400;;mg;;"(200mg): (S0-T5-R3)-(S24-T5-R3)-(S48-T5-R3)-(S72-T5-R3)-(S96-T5-R3)-(S120-T5-R3)-(S144-T5-R3)-(S168-T5-R3)-(S192-T5-R3)-(S216-T5-R3)-(S240-T5-R3)-(S264-T5-R3)-(S288-T5-R3)-(S312-T5-R3)-(S336-T5-R3)-(S360-T5-R3)-(S384-T5-R3); (400mg): S15-T24-R17";h;"(200mg): MD TID (17 days); (400mg): OD (17 days)";"(200mg): MD TID (Day 15-31); (400mg): OD (Day 15-31); 1 g/d";;;;;;;;;
1344;Kienlen 1993;https://link,springer,com/article/10,1007/BF03259596;Alfentanil + Cimetidine;Alfentanil;Cimetidine;IV;IV;Reversible_Inhibition;Serum;2,803149606;Approx, Avg;;;;;;;0;inf;48;inf;h;;;1200;;mg;IV;0-24;h;MD OD (2 days);MD OD (Day 1-2);;;;;15 to 20 mg/kg;;;;
1346;Elliott 1984;https://pubmed,ncbi,nlm,nih,gov/6152615/;Midazolam/cimetidine;Midazolam;Cimetidine;PO;PO;Reversible_Inhibition;Plasma;2,016042781;Approx, Avg;;;2,383333333;Approx, Avg;;;0;inf;26,5;inf;h;;;200/400;;mg;;"(200mg): 0-6-12-24; (400mg): 18";h;"(200mg): MD TID (1 day), OD (1 day); (400mg): OD (1 day)";"(200mg): MD TID (Day 1), OD (Day 2); (400mg): OD (Day 2)";;;;;;;;;
211;Jacobson 2004;https://pubmed,ncbi,nlm,nih,gov/15518608/;Pravastatin with Itraconazole;Pravastatin;Itraconazole;PO;PO;;Plasma;1,117021277;Approx, Avg;11;% Change;1,140625;Approx, Avg;14;% Change;0;inf;696;inf;h;;;200;;mg;;S24-T24-R29;h;MD OD (29 days);MD OD (Day 2-30);;;;;;;;;
1124;Neuvonen 1998;https://pubmed,ncbi,nlm,nih,gov/9542477/;Pravastatin with Itraconazole;Pravastatin;Itraconazole;PO;PO;;Plasma;1,7;Arith, Mean;;;2,5;arith, Mean;;;0;inf;74;inf;h;;;200;;mg;PO;0-24-48-72;h;MD OD (4 days);MD;;Sporanox, Janssen Pharma, Beerse, Belgium;;;Dosing at 7:30 am for 4 days;;;;
1126;Kantola 2000;https://pubmed,ncbi,nlm,nih,gov/10952477/;Pravastatin with Fluconazole;Pravastatin;Fluconazole;PO;PO;;Plasma;1,4;Arith, Mean;0,5-2,7;Relative to control (range);1,3;arith, Mean;0,3-2,8;Relative to control (range);0;inf;73;inf;h;;;400 / 200;;mg;PO;0-24-48-72;h;MD OD (4 days);MD, Day1: 400mg, Day 2-4: 200mg;;Diflucan, Pfizer Inc,, N,Y,;;;;;;;
1129;Maeda 2011;https://pubmed,ncbi,nlm,nih,gov/21832990/;Pravastatin with Itraconazole;Pravastatin;Itraconazole;PO;PO;;Plasma;1,472361809;Approx, Avg;;;;;;;0;8;1;9;h;;AUCR was calculated by using these values: AUC(0-t)/dose, area under the plasma concentration-time curve from time 0 to t hours normalized by dose in each phase,;200;;mg;IV;0;h;SD;;;Itrizole 1% solution;60;;1h before oral solution;;;;
1130;Maeda 2011;https://pubmed,ncbi,nlm,nih,gov/21832990/;Pravastatin with Rifampicin;Pravastatin;Rifampicin;PO;PO;;Plasma;4,639865997;Approx, Avg;;;;;;;0;8;0;8;h;1;AUCR was calculated by using these values: AUC(0-t)/dose, area under the plasma concentration-time curve from time 0 to t hours normalized by dose in each phase,;600;;mg;PO;0;h;SD;;;four 150mg Rifadin capsules;;;at the same time of oral solution;;;;
1146;Azie 1998;https://pubmed,ncbi,nlm,nih,gov/9797793/;with Diltiazem;Pravastatin;Diltiazem;PO;PO;;Plasma;1,027027027;Approx, Avg;;;1,303030303;Approx, Avg;;;0;inf;325;inf;h;;;120;;mg;;S0-T12-R42;h;MD: BID for 2 weeks;2 weeks of 120 mg diltiazem twice a day;;Cardizem SR;;;;;;;
1149;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 2, 2 mg Rifampicin;Pravastatin;Rifampicin;PO;PO;;Plasma;833;geom mean;"(0,716; 0,970)";90%CI;856;geom mean;"(0,690; 1,063)";90%CI;0;inf;276;inf;h;1;;2;;mg;PO;S0-T24-R18;h;MD OD (18 days);Acc, to Table 2: RIF was given q,d, from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg);;;;;;;;;
1150;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 1, 10 mg Rifampicin;Pravastatin;Rifampicin;PO;PO;;Plasma;813;geom mean;"(0,713; 0,926)";90%CI;788;geom mean;"(0,660; 0,939)";90%CI;0;inf;276;inf;h;1;;10;;mg;PO;S0-T24-R18;h;MD OD (18 days);Acc, to Table 2: RIF was given q,d, from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg);;;;;;;;;
1151;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 1, 75 mg Rifampicin;Pravastatin;Rifampicin;PO;PO;;Plasma;421;geom mean;"(0,350; 0,505)";90%CI;407;geom mean;"(0,325; 0,511)";90%CI;0;inf;708;inf;h;1;;10, 75;;mg;PO;S0-T24-R18 (10 mg), S432-T24-R18 (75 mg);h;MD OD (18 day 10 mg, 18 days 75 mg);Acc, to Table 2: RIF was given q,d, from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg);;;;;;;;;
1152;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 2, 600 mg Rifampicin;Pravastatin;Rifampicin;PO;PO;;Plasma;416;geom mean;"(0,333; 0,521)";90%CI;473;geom mean;"(0,361; 0,621)";90%CI;0;inf;708;inf;h;1;;2, 600;;mg;PO;S0-T24-R18 (2 mg), S432-T24-R18 (600 mg);h;MD OD (18 day 2 mg, 18 days 600 mg);Acc, to Table 2: RIF was given q,d, from DAY 9 to DAY 26 (RIF 10mg and 2mg) and DAY 27 to DAY 44 (RIF 75mg and 600mg);;;;;;;;;
1169;Jacobson 2004;https://pubmed,ncbi,nlm,nih,gov/15518608/;Pravastatin with Verapamil;Pravastatin;Verapamil;PO;PO;;Plasma;1,315789474;Approx, Avg;31;%Change;1,40625;Approx, Avg;42;%Change;0;24;72;96;h;;AUCRVar and CmaxR Var taken from %Change (Table 1);120 IR / 480 ER;;mg;;0-12-36-60;h;MD: Day 1: 120mg IR in the morning, Day 2-4: 480mg ER in the evening;120mg immediate-released (IR), 480mg extended-released (ER);;;;;;;;;
1172;Jacobson 2004;https://pubmed,ncbi,nlm,nih,gov/15518608/;Pravastatin with Clarithromycin;Pravastatin;Clarithromycin;PO;PO;;Plasma;2,111111111;Approx, Avg;110;%Change;2,277777778;Approx, Avg;128;%Change;144;154;168;181,5;h;;AUCRVar and CmaxR Var taken from %Change (Table 4);500;;mg;;S0-T12-R18;h;MD BID (9 days);MD: bid for 9 days;;;;;;;;;
1174;Yee 2019;https://pubmed,ncbi,nlm,nih,gov/30982223/;Pravastatin with Cyclosporin;Pravastatin;Cyclosporin;PO;PO;;Plasma;3,419753086;Approx, Avg;;;3,198113208;Approx, Avg;;;0;12;11;23;h;;AUCR & CmaxR: (PRA + CsA) / (PRA + Placebo);100;;mg;;0-10;h;MD OD (2 days);MD: Day 1 evening: 100mg, Day 2 morning: 100mg;;;;;;;;;fasted at least for 10h for dosing at Day 2
1183;Becquemont 2007;https://pubmed,ncbi,nlm,nih,gov/17301736/;with Amiodarone;Pravastatin;Amiodarone;PO;PO;;Plasma;0,899854862;Approx, Avg;86% (63-118%);90% CI;0,767511177;Approx, Avg;72% (47-109%);90% CI;0;24;72;96;h;;AUCRVar and CmaxR Var taken from Point Estimates (Table 1);400;;mg;PO;S0-T24-R4;h;MD: OD (4 days);MD, q,d, for 4 days;;amiodarone (Cordarone(R), 200 mg tablets, Sanofi-Aventis, France);;;;fasted;overnight fast;;
1185;Mazzu 2000;https://pubmed,ncbi,nlm,nih,gov/11061579/;Pravastatin + Itraconazole;Pravastatin;Itraconazole;PO;PO;;Plasma;1,51;Geom LS means;1,10 -2,06;90% CI;1,24;Geom LS means;0,86 - 1,79;90% CI;0;inf;100;inf;h;;"AUC(0-tn): AUCR: 1,56 (Geom LS means); AUCR Var: 1,18-2,06 (90% CI)";200;;mg;PO;S0-T24-R5;h;MD OD (5 days);MD: OD Day 6-10;;;;;Dosing of ITZ at 6PM  ﾱ 30 min;;;;
1198;Kyrklund 2003;https://pubmed,ncbi,nlm,nih,gov/12811363/;with Gemfibrozil;Pravastatin;Gemfibrozil;PO;PO;;Plasma;2,018705036;Approx Avg;;;1,809954751;Approx, Avg;;;0;inf;49;inf;h;;"Cmax(mg/L) of Gemfibrozil: 32+/- 8,5; AUC(1-25)(mg*h/L): 209+/- 97 [arith mean+/- SD]; Difference between phases: AUC(0-inf): 141,6 (12,6 to 270,6) [mean and 95%CI]; AUC(0-24): 141,1 (12,4 to 269,9) [mean and 95%CI]; Cmax: 53,7 (ﾖ12,1 to 119,6) [mean and 95%CI]";600;;mg;PO;S0-T12-R6;h;MD BID (3 days);MD: BID Day1-3;;"one 600-mg tablet of Lopid; Parke-Davis, Freiburg, Germany";;;Dosing of Gemfibrozil at 8 AM and 8 PM;;;;"overnight fast on Day 3, At 8AM: gemfibrozil was given; at 9AM: pravastatin was given; 3h after pravastatin administration standard meal was given,"
1200;Kyrklund 2004;https://pubmed,ncbi,nlm,nih,gov/14748817/;with Rifampicin (MD 600 mg);Pravastatin;Rifampicin;PO;PO;;Plasma;0,69084507;Approx Avg;;;0,788018433;Approx, Avg;;;0;inf;113;inf;h;1;"Difference between phases: AUC(0-inf): -51,9ﾖ-0,4 [95%CI]; AUC(0-12): (-51,7 to -0,4) [95%CI]; Cmax: -24,9ﾖ5,1 [95%CI]";600;;mg;PO;S0-T24-R5;h;MD OD (5 days);MD: OD Day 1-5;;Rifarm, Pharmacal, Helsinki, Finland;;;Dosing at 4 PM daily for 5 days;;;;
6010;Yasui-Furukori 2004;https://pubmed,ncbi,nlm,nih,gov/15025747/;Omeprazoleﾠ+ﾠFluvoxamineﾠ(EM);Omeprazole;Fluvoxamine;PO;PO;;Plasma;5,34;;;;3,48;;;;120;inf;120;inf;h;;EM;50;;mg;PO;;;;;;;;;;;;;
6011;Yasui-Furukori 2004;https://pubmed,ncbi,nlm,nih,gov/15025747/;Omeprazoleﾠ+ﾠFluvoxamineﾠ(PM);Omeprazole;Fluvoxamine;PO;PO;;Plasma;1,21;;;;1,12;;;;120;inf;120;inf;h;;PM;50;;mg;PO;;;;;;;;;;;;;
6020;Cho 2002;https://pubmed,ncbi,nlm,nih,gov/11966672/;Omeprazole + Moclobemide (EM);Omeprazole;Moclobemide;PO;PO;;Plasma;2,05;;;;1,67;;;;0;inf;0;inf;h;;EM;300;;mg;PO;;;;;;;;;;;;;
6021;Cho 2002;https://pubmed,ncbi,nlm,nih,gov/11966672/;Omeprazole + Moclobemide (PM);Omeprazole;Moclobemide;PO;PO;;Plasma;1,16;;;;0,97;;;;0;inf;0;inf;h;;PM;300;;mg;PO;;;;;;;;;;;;;
6030;Yao 2003;https://pubmed,ncbi,nlm,nih,gov/12695344/;S-Mephenytoine + Fluvoxamine;S-Mephenytoine;Fluvoxamine;PO;PO;;Plasma;4,64;;;;2,12;;;;176;inf;176;inf;h;;;27,5;;mg;PO;;;;;;;;;;;;;
6031;Yao 2003;https://pubmed,ncbi,nlm,nih,gov/12695344/;S-Mephenytoine + Fluvoxamine;S-Mephenytoine;Fluvoxamine;PO;PO;;Plasma;6,7;;;;2,4;;;;176;inf;176;inf;h;;;45,8;;mg;PO;;;;;;;;;;;;;
6032;Yao 2003;https://pubmed,ncbi,nlm,nih,gov/12695344/;S-Mephenytoine + Fluvoxamine;S-Mephenytoine;Fluvoxamine;PO;PO;;Plasma;9,89;;;;2,42;;;;176;inf;176;inf;h;;;64,1;;mg;PO;;;;;;;;;;;;;
6040;Yu 2001;https://pubmed,ncbi,nlm,nih,gov/11309556/;Moclobemide + Omeprazole;Moclobemide;Omeprazole;PO;PO;;Plasma;1,31;;;;1,11;;;;0;inf;0;inf;h;;;40;;mg;PO;;;;;;;;;;;;;
6050;Granfors 2005;https://pubmed,ncbi,nlm,nih,gov/16198659/;Tizanidine + Ethinylestradiol;Tizanidine;Ethinylestradiol;PO;PO;;Plasma;3,92;;;;3,02;;;;480;inf;480;inf;h;;;20;;mg;PO;;;;;;;;;;;;;
6060;Jeppesen 1996;https://pubmed,ncbi,nlm,nih,gov/8807660/;Caffeine + Fluvoxamine;Caffeine;Fluvoxamine;PO;PO;;Plasma;7,16;;;;1,09;;;;168;inf;169;inf;h;;;100;;mg;PO;;;;;;;;;;;;;
6061;Culm-Merdek 2005;https://pubmed,ncbi,nlm,nih,gov/16236038/;Caffeine + Fluvoxamine;Caffeine;Fluvoxamine;PO;PO;;Plasma;13,71;;;;1,4;;;;25;inf;25;inf;h;;;100;;mg;PO;;;;;;;;;;;;;
6070;Granfors 2004;https://pubmed,ncbi,nlm,nih,gov/14998432/;Tizanidine + Fluvoxamine;Tizanidine;Fluvoxamine;PO;PO;;Plasma;33;;;;12,1;;;;73;inf;73;inf;h;;;100;;mg;PO;;;;;;;;;;;;;
6080;Joeres 1987;https://pubmed,ncbi,nlm,nih,gov/3628469/;Caffeine + Mexiletine;Caffeine;Mexiletine;PO;PO;;Plasma;2,83;;;;1,89;;;;0;inf;0;inf;h;;;200;;mg;PO;;;;;;;;;;;;;
6090;Momo 2010;https://pubmed,ncbi,nlm,nih,gov/19789372/;Tizanidine + Mexiletine;Tizanidine;Mexiletine;PO;PO;;Plasma;3,42;;;;3,22;;;;;inf;;inf;h;;;50;;mg;PO;;;;;;;;;;;;;
6100;Kusumoto 2001;https://pubmed,ncbi,nlm,nih,gov/11240973/;Mexiletine + Fluvoxamine;Mexiletine;Fluvoxamine;PO;PO;;Plasma;1,55;;;;1,16;;;;168;inf;168;inf;h;;;50;;mg;PO;;;;;;;;;;;;;
6110;Balogh 1995;https://pubmed,ncbi,nlm,nih,gov/7589032/;Caffeineﾠ+ﾠEthinylestradiol;Caffeine;Ethinylestradiol;PO;PO;;Plasma;2,13;;;;1,15;;;;480;inf;480;inf;h;;;0,03;;mg;PO;;;;;;;;;;;;;
1350;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 2, 2 mg Rifampicin;Midazolam;Rifampicin;PO;PO;Induction;Plasma;769;GMR;0,730-0,810;90%CI;0,79;GMR;0,738-0,846;90%CI;0;inf;228;660;h;1;;2;;mg;PO;S0-T24-R18;h;MD OD (18 days);;;;;;;;;;
1351;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 1, 10 mg Rifampicin;Midazolam;Rifampicin;PO;PO;Induction;Plasma;398;GMR;0,359-0,441;90%CI;516;GMR;0,460-0,579;90%CI;0;inf;228;660;h;1;;10;;mg;PO;S0-T24-R18;h;MD OD (18 days);;;;;;;;;;
1352;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 1, 75 mg Rifampicin;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,0916;GMR;0,0795-0,1055;90%CI;149;GMR;0,130-0,171;90%CI;0;inf;660;inf;h;1;;first 10, then 75;;mg;PO;S0-T24-R18 (10 mg), S432-T24-R18 (75 mg);h;MD OD (18 days 10 mg, then 18 days 75 mg);;;;;;;;;;
1353;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569723/;Cohort 2, 600 mg Rifampicin;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,0859;GMR;0,0695-0,1061;90%CI;139;GMR;0,112-0,172;90%CI;0;inf;660;inf;h;1;;first 2, then 600;;mg;PO;S0-T24-R18 (2 mg), S432-T24-R18 (600 mg);h;MD OD (18 days 2 mg, then 18 days 600 mg);;;;;;;;;;
1355;Bj�rkhem-Bergman 2013;https://pubmed,ncbi,nlm,nih,gov/23674608/;with Rifampicin 10 mg;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,5;GMR;;;;;;;0;10;336;346;h;1;AUCR inverted from CL ratio;10;;mg;PO;S0-T24-R14;h;MD OD (14 days);;;Rifadin oral suspension;;;;;;;
1356;Bj�rkhem-Bergman 2013;https://pubmed,ncbi,nlm,nih,gov/23674608/;with Rifampicin 20 mg;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,384615385;GMR;;;;;;;0;10;336;346;h;1;AUCR inverted from CL ratio;20;;mg;PO;S0-T24-R14;h;MD OD (14 days);;;Rifadin oral suspension;;;;;;;
1357;Bj�rkhem-Bergman 2013;https://pubmed,ncbi,nlm,nih,gov/23674608/;with Rifampicin 100 mg;Midazolam;Rifampicin;PO;PO;Induction;Plasma;0,25;GMR;;;;;;;0;10;336;346;h;1;AUCR inverted from CL ratio;100;;mg;PO;S0-T24-R14;h;MD OD (14 days);;;Rifadin oral suspension;;;;;;;
1362;Chattopadhyay 2018;https://pubmed,ncbi,nlm,nih,gov/30171692/;with Perpetrator (Rifampicin);Midazolam;Rifampicin;PO;PO;Induction;Plasma;141;GMR;28,8;geom, CV%;138;GMR;20,8;geom, CV%;0;inf;168;inf;h;1;Subjects received a single dose of vilaprisan 4 mg simultaneously with midazolam,;600;;mg;PO;0-24-48-72-96-120-144-180-192-216-240;h;MD OD (11 days);;;;;;;;;;
1392;Ahonen 1997;https://pubmed,ncbi,nlm,nih,gov/9049584/;Midazolam with perpetrator fluconazole i,v;Midazolam;Fluconazole;PO;IV;Reversible_Inhibition;Plasma;3,08;Approx, Avg;;;1786;Approx, Avg;;;1;18;1;18;h;;;400;;mg;IV;0;h;SD;;;;60;;;Fasted;;;
1393;Ahonen 1997;https://pubmed,ncbi,nlm,nih,gov/9049584/;Midazolam with perpetrator fluconazole oral;Midazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;3,41;Approx, Avg;;;2296;Approx, Avg;;;1;18;1;18;h;;;400;;mg;PO;0;h;SD;;;Diflucan ;;150;;Fasted;;;
1394;Varhe 1996c;https://pubmed,ncbi,nlm,nih,gov/8904618/;Triazolam with perpetrator fluconazole 50mg ;Triazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;1587;Approx, Avg;;;1467;Approx, Avg;;;73;92;73;92;h;;;50;;mg;PO;0-24-48-72;h;MD for 4 days;victim administered 1 h after last dose;;Diflucan ;;150;;Fasted;;;
1395;Varhe 1996c;https://pubmed,ncbi,nlm,nih,gov/8904618/;Triazolam with perpetrator fluconazole 100mg ;Triazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;1,99;Approx, Avg;;;1,4;Approx, Avg;;;73;92;73;92;h;;;100;;mg;PO;0-24-48-73;h;MD for 4 days;victim administered 1 h after last dose;;Diflucan ;;150;;Fasted;;;
1396;Varhe 1996c;https://pubmed,ncbi,nlm,nih,gov/8904618/;Triazolam with perpetrator fluconazole 200mg ;Triazolam;Fluconazole;PO;PO;Reversible_Inhibition;Plasma;3652;Approx, Avg;;;2,33;Approx, Avg;;;73;92;73;92;h;;;200;;mg;PO;0-24-48-74;h;MD for 4 days;victim administered 1 h after last dose;;Diflucan ;;150;;Fasted;;;
1398;Palkama 1998;https://pubmed,ncbi,nlm,nih,gov/9661572/;Alfentanil with perpetrator fluconazole i,v,;Alfentanil;Fluconazole;IV;IV;Reversible_Inhibition;Plasma;2,07;Approx, Avg;;;1,2;Approx, Avg;;;1;11;1;11;h;;;400;;mg;IV;0;h;SD;;;;;;;;;;
1399;Palkama 1998;https://pubmed,ncbi,nlm,nih,gov/9661572/;Alfentanil with perpetrator fluconazole po;Alfentanil;Fluconazole;IV;PO;Reversible_Inhibition;Plasma;1,97;Approx, Avg;;;1,04;Approx, Avg;;;1;11;1;11;h;;;400;;mg;PO;0;h;SD;;;Diflucan;;;;Fasted;;;
895;Burstein 2000;https://pubmed,ncbi,nlm,nih,gov/11180020/;After St Johnﾒs Wort;Carbamazepine;St John's Wort;0;PO;Induction;Plasma;0,9976024;GMR;1,179883;Geom, SD;1,053142;GMR;1,241582;Geom, SD;480;504;816;840;h;;;300;;mg;PO;S504-T8-R42;h;MD;The St Johnﾒs Wort preparation used in this study was standardized to 0,3% hypericin (confirmed in our laboratory with a United States Pharmacopeia/National Formulary method);;;;;;Fed;;;
897;Burstein 2000;https://pubmed,ncbi,nlm,nih,gov/11180020/;After St Johnﾒs Wort;Carbamazepine-10-11-epoxide;St John's Wort;0;PO;Induction;Plasma;1,106134;GMR;1,304603;Geom, SD;1,104909;GMR;1,34381;Geom, SD;480;504;816;840;h;;;300;;mg;PO;S504-T8-R42;h;MD;The St Johnﾒs Wort preparation used in this study was standardized to 0,3% hypericin (confirmed in our laboratory with a United States Pharmacopeia/National Formulary method);;;;;;Fed;;;
900;Dalton 1985a;https://pubmed,ncbi,nlm,nih,gov/3987645/;Treatment with cimetidine;Carbamazepine;Cimetidine;0;PO;Reversible_Inhibition;Plasma;1,254777;Approx, Avg;;;;;;;0;inf;48;inf;h;;;300;;mg;PO;(S0-T24-R9)-(S4-T24-R9)-(S8-T24-R9)-(S16-T24-R9);h;MD;;;;;;;;;;
901;Dalton 1985a;https://pubmed,ncbi,nlm,nih,gov/3987645/;Treatment with cimetidine;Carbamazepine-10-11-epoxide;Cimetidine;0;PO;Reversible_Inhibition;Plasma;1,267606;Approx, Avg;;;;;;;0;inf;48;inf;h;;;300;;mg;PO;(S0-T24-R9)-(S4-T24-R9)-(S8-T24-R9)-(S16-T24-R9);h;MD;;;;;;;;;;
465;Barzaghi 1987;https://pubmed,ncbi,nlm,nih,gov/3440106/;With erythromycin;Carbamazepine;Erythromycin;0;PO;Mechanism_based_Inactivation;Serum;1,319647;Approx, Avg;;;0,9615385;Approx, Avg;;;0;inf;144;inf;h;;;500;;mg;PO;S0-T8-R30;h;MD;Time of carbamazepine administration relative to erythromycin administration not reported;Erythromycin stearate;;;;;;;;
466;Barzaghi 1987;https://pubmed,ncbi,nlm,nih,gov/3440106/;With erythromycin;Carbamazepine-10-11-epoxide;Erythromycin;0;PO;Mechanism_based_Inactivation;Serum;624;Approx, Avg;;;0,5840131;Approx, Avg;;;0;inf;144;inf;h;;;500;;mg;PO;S0-T8-R30;h;MD;Time of carbamazepine administration relative to erythromycin administration not reported;Erythromycin stearate;;;;;;;;
959;Ji 2008;https://pubmed,ncbi,nlm,nih,gov/18519918/;Efavirenz + Carbamazepine, treatment (Arm 1);Efavirenz;Carbamazepine;0;PO;Induction;Plasma;0,64;GMR;0,60-0,68;90%CI;0,79;GMR;0,74-0,85;90%CI;312;336;816;840;h;;;200/400;;mg;PO;"Days15-17: S336-T24-R3; Days18-20: S408-T12-R6; Days21-35: S480-T24-R15";h;MD;;tablets of 200-mg strength (Novartis Pharmaceuticals Co, East Hanover, New Jersey);;;;;Fasted;;;
961;Ji 2008;https://pubmed,ncbi,nlm,nih,gov/18519918/;Carbamazepine + Efavirenz, treatment (Arm 2);Carbamazepine;Efavirenz;0;PO;Induction;Plasma;0,73;GMR;0,67-0,80;90%CI;0,8;GMR;0,76-0,85;90%CI;480;504;816;840;h;;;600;;mg;PO;S504-T24-R14;h;MD;;tablets of 600-mg strength (Bristol-Myers Squibb Co, Princeton, New Jersey);;;;;Fasted;;;
963;Ji 2008;https://pubmed,ncbi,nlm,nih,gov/18519918/;Carbamazepine + Efavirenz, treatment (Arm 2);Carbamazepine-10-11-epoxide;Efavirenz;0;PO;Induction;Plasma;0,99;GMR;0,85-1,15;90%CI;1,05;GMR;0,91-1,22;90%CI;480;504;816;840;h;;;600;;mg;PO;S504-T24-R14;h;MD;;tablets of 600-mg strength (Bristol-Myers Squibb Co, Princeton, New Jersey);;;;;Fasted;;;
1420;Miles 1989;https://pubmed,ncbi,nlm,nih,gov/2911854/;CBZ during ERY;Carbamazepine;Erythromycin;0;PO;Mechanism_based_Inactivation;Serum;;;;;;;;;;;;;;;;250;;mg;PO;S336-T6-R12;h;MD;;Erythromycin base;ERYC, lot no,CL102037, Warner-Lambert, Ann Arbor, MI, USA;;;;;;;
1421;Miles 1989;https://pubmed,ncbi,nlm,nih,gov/2911854/;CBZE during ERY;Carbamazepine-10-11-epoxide;Erythromycin;0;PO;Mechanism_based_Inactivation;Serum;;;;;;;;;;;;;;;;250;;mg;PO;S336-T6-R12;h;MD;;Erythromycin base;ERYC, lot no,CL102037, Warner-Lambert, Ann Arbor, MI, USA;;;;;;;
1154;Wong 1983;https://pubmed,ncbi,nlm,nih,gov/6831824/;with erythromycin;Carbamazepine;Erythromycin;0;PO;Mechanism_based_Inactivation;Plasma;1,239669;Approx, Avg;;;;;;;0;inf;120;inf;h;;;250;;mg;PO;S0-T6-R32;h;MD;Time of carbamazepine administration relative to erythromycin administration not reported;;;;;;;;;
1456;Furukori 1998;https://pubmed,ncbi,nlm,nih,gov/9536449/;treatment with placebo;Alprazolam;Carbamazepine;0;PO;Induction;Plasma;0,4225352;Approx, Avg;;;1,111111;Approx, Avg;;;0;inf;170;inf;h;;;300;;mg;PO;S0-T8-R30;h;MD;;;Tegretol (Novartis Pharma, Tokyo, Japan);;;;;;;
1460;Lutz 2018;https://pubmed,ncbi,nlm,nih,gov/29569712/;After co-administration with carbamazepine;Midazolam;Carbamazepine;0;PO;Induction;Plasma;211;GMR;0,183-0,244;90%CI;318;GMR;0,281-0,361;90%CI;;;;;;;;;;;;;;;;;;;;;;;;
